

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 24, 2005, 14:36:22 ; Search time 151 Seconds  
(without alignments)  
919.392 Million cell updates/sec

Title: US-09-744-804A-78  
Perfect score: 2110  
Sequence: 1 MPRPRLAALCGALLCAPSL.....RLPVAHNRIRALRLILGCG 387

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 444336

Minimum DB seq length: 0  
Maximum DB seq length: 10

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :  
1: A.Geneseq\_23Sep04:\*  
2: geneseqp1980s:\*  
3: geneseqp1990s:\*  
4: geneseqp2000s:\*  
5: geneseqp2001s:\*  
6: geneseqp2002s:\*  
7: geneseqp2003as:\*  
8: geneseqp2003bs:\*  
9: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	54	2.6	9	3	AAV82844
2	53	2.5	9	3	AAV82840
3	49	2.3	9	3	AAV82841
4	48	2.3	9	5	ABG32319
5	46	2.2	9	3	AAV82843
6	45	2.1	10	6	ABJ50137
7	45	2.1	10	6	ABJ50137
8	45	2.1	10	6	ABJ51815
9	45	2.1	10	6	ABJ40507
10	45	2.1	10	6	ABJ39695
11	45	2.1	10	6	ABJ54131
12	45	2.1	10	6	ABJ40876
13	45	2.1	10	6	ABJ53401
14	45	2.1	10	6	ABJ51353
15	45	2.1	10	6	ABJ52549
16	45	2.1	10	6	ABJ50895
17	44	2.1	9	3	AAV82846
18	44	2.1	9	6	ABJ42681
19	44	2.1	9	6	ABJ44746
20	44	2.1	9	6	ABJ44094
21	44	2.1	9	6	ABJ46023
22	44	2.1	9	6	ABJ48298
23	44	2.1	9	6	ABJ47602
24	44	2.1	9	6	ABJ41130
25	44	2.1	9	6	ABJ48967

26	44	2.1	9	6	ABJ43478	Abj43478	151P3D4 C
27	44	2.1	9	6	ABJ19878	Abj19878	MHC bind1
28	44	2.1	10	6	ABJ50787	Abj50787	151P3D4 C
29	44	2.1	10	6	ABJ40913	Abj40913	151P3D4 C
30	44	2.1	10	6	ABJ51010	Abj51010	151P3D4 C
31	44	2.1	10	6	ABJ50205	Abj50205	151P3D4 C
32	44	2.1	10	6	ABJ54067	Abj54067	151P3D4 C
33	44	2.1	10	6	ABJ50314	Abj50314	151P3D4 C
34	44	2.1	10	6	ABJ51009	Abj51009	151P3D4 C
35	44	2.1	10	6	ABJ52619	Abj52619	151P3D4 C
36	44	2.1	10	6	ABJ41328	Abj41328	151P3D4 C
37	44	2.1	10	6	ABJ40519	Abj40519	151P3D4 C
38	44	2.1	10	6	ABJ50264	Abj50264	151P3D4 C
39	44	2.1	10	6	ABJ52074	Abj52074	151P3D4 C
40	44	2.1	10	6	ABJ53479	Abj53479	151P3D4 C
41	44	2.1	10	6	ABJ51324	Abj51324	151P3D4 C
42	44	2.1	10	6	ABJ52807	Abj52807	151P3D4 C
43	44	2.1	10	6	ABJ41714	Abj41714	151P3D4 C
44	44	2.1	10	6	ABJ53219	Abj53219	151P3D4 C
45	44	2.1	10	6	ABJ54066	Abj54066	151P3D4 C

## ALIGNMENTS

RESULT 1	AAV82844	standard; peptide; 9 AA.
ID	AAV82844	
AC	AAV82844;	
DT	19-JUN-2000	(first entry)
XX		
DE		Lactadherin (BA-46) peptide fragment (tumour associated antigen).
XX		
KW		Tumour associated antigen peptide; TAA; cancer; carcinoma; treatment;
KW		prevention; cure; anti-tumour vaccine; metastases; breast; bladder;
KW		prostate; pancreas; ovary; thyroid; colon; stomach; carcinoma;
KW		MHC Class I; HLA-A2; human; Major Histocompatibility Complex; uroplakin;
KW		prostate specific antigen; prostate specific membrane antigen;
KW		prostate acid phosphatase; mucin; lactadherin;
KW		teratocarcinoma derived growth factor; PSA; PSMa; PAP; CRIPTO-1.
XX		
OS		Homo sapiens.
XX		
PN		WO200006723-A1.
XX		
PD		10-FEB-2000.
XX		
PF		29-JUL-1999; 99WO-IL000417.
XX		
PR		30-JUL-1998; 98IL-00125608.
XX		
PA		(YEDA ) YEDA RES & DEV CO LTD.
PA		(BIOT-) BIO-TECHNOLOGY GEN CORP.
XX		
PI		Bisenbach L, Carmon L, Tirosh B, Bar-Haim E, Paz A, Frickin M;
PI		Fitzner-Aktas C;
XX		
XX		WPI; 2000-205463/18.
DR		
XX		
PT		Tumor associated antigen peptides, especially derived from uroplakin,
PT		useful as vaccines to prevent or cure cancers including breast, bladder,
PT		prostate, pancreas, ovary, thyroid, colon and stomach.
XX		
PS		Claim 17; Page 100; 113pp; English.
XX		
CC		Tumour associated antigen peptides (TAA) may be used for the treatment,
CC		prevention and cure of cancer or cancer metastases. The cancer may be
CC		breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach, head
CC		or neck cancer or a carcinoma. The tumour associated antigens are
CC		presentable to the immune system by HLA-A2 molecules and are generally
CC		between 8 to 10 amino acids in length. The amino acids located at

CC positions 2 and 9 of the tumour associated antigens are the anchor  
CC residues which participate in the binding to MHC class I molecules, more  
CC specifically HLA-A2. More tumour associated antigens are described in  
CC GENESKO records AAY82806-Y82882. Those tumour associated antigens  
CC described in records AAY82806-Y82824 and AAY82855-Y82869 are derived  
CC from Uroplakin, such as Uroplakin II, Uroplakin Ia, Uroplakin III and  
CC Uroplakin Ib. Those described in records AAY82825-Y82829 are derived from  
CC prostate specific antigen (PSA). Those described in records AAY82830-  
CC Y82835 are derived from prostate specific membrane antigen (PSMA). Those  
CC described in records Y82836-AAY82839 are derived from prostate acid  
CC phosphatase (PAP). Those described in records AAY82840-Y82846 are derived  
CC from Lactadherin (BA-46). Those described in records AAY82847-Y82854 are  
CC derived from Mucin and those described in records AAY82871-Y82882 are  
CC derived from Teratocarcinoma derived growth factor (CRIPTO-1)

SO Sequence 9 AA;

Query Match 2.6%; Score 54; DB 3; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 |||||  
Db 1 GLOHWPBL 9

#### RESULT 2

AAV82840 standard; peptide; 9 AA.

AAV82840;

19-JUN-2000 (first entry)

Lactadherin (BA-46) peptide fragment (tumour associated antigen).

Tumour associated antigen peptide; TAA; cancer; carcinoma; treatment;  
prevention; cure; anti-tumour vaccine; metastases; breast; bladder;  
prostate; pancreas; ovary; thyroid; colon; stomach; carcinoma;  
MHC Class I; HLA-A2; human; Major Histocompatibility Complex; uroplakin;  
prostate specific antigen; prostate specific membrane antigen;  
prostate acid phosphatase; mucin; lactadherin;  
teratocarcinoma derived growth factor; PSA; PSMA; PAP; CRIPTO-1.

Homo sapiens.

WO200006723-A1.

10-FEB-2000.

29-JUL-1999; 99WO-IL000417.

30-JUL-1998; 98IL-00125608.

(YEDA ) YEDA RES & DEV CO LTD.  
(BIOT-) BIO-TECHNOLOGY GEN CORP.

Bisenbach L, Carnon L, Tirosh B, Bar-Haim E, Paz A, Fridkin M;  
Fitzner-Ahtas C;

WPI; 2000-205463/18.

Tumour associated antigen peptides, especially derived from uroplakin,  
PT useful as vaccines to prevent or cure cancers including breast, bladder,  
PT prostate, pancreas, ovary, thyroid, colon and stomach.

Claim 17; Page 99; 113pp; English.

Tumour associated antigen peptides (TAA) may be used for the treatment,  
CC prevention and cure of cancer or cancer metastases. The cancer may be  
CC breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach, head  
CC or neck cancer or a carcinoma. The tumour associated antigens are  
CC presentable to the immune system by HLA-A2 molecules and are generally

CC between 8 to 10 amino acids in length. The amino acids located at  
CC positions 2 and 9 of the tumour associated antigens are the anchor  
CC residues which participate in the binding to MHC class I molecules, more  
CC specifically HLA-A2. More tumour associated antigens are described in  
CC GENESKO records AAY82806-Y82882. Those tumour associated antigens  
CC described in records AAY82806-Y82824 and AAY82855-Y82869 are derived  
CC from Uroplakin, such as Uroplakin II, Uroplakin Ia, Uroplakin III and  
CC Uroplakin Ib. Those described in records AAY82825-Y82829 are derived from  
CC prostate specific antigen (PSA). Those described in records AAY82830-  
CC Y82835 are derived from prostate specific membrane antigen (PSMA). Those  
CC described in records Y82836-AAY82839 are derived from prostate acid  
CC phosphatase (PAP). Those described in records AAY82840-Y82846 are derived  
CC from Lactadherin (BA-46). Those described in records AAY82847-Y82854 are  
CC derived from Mucin and those described in records AAY82871-Y82882 are  
CC derived from Teratocarcinoma derived growth factor (CRIPTO-1)

SO Sequence 9 AA;

Query Match 2.5%; Score 53; DB 3; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 271 KOGFNAMV 279  
Db 1 KOGFNAMV 9

#### RESULT 3

AAV82841 standard; peptide; 9 AA.

AAV82841;

19-JUN-2000 (first entry)

Lactadherin (BA-46) peptide fragment (tumour associated antigen).

Tumour associated antigen peptide; TAA; cancer; carcinoma; treatment;  
prevention; cure; anti-tumour vaccine; metastases; breast; bladder;  
prostate; pancreas; ovary; thyroid; colon; stomach; carcinoma;  
MHC Class I; HLA-A2; human; Major Histocompatibility Complex; uroplakin;  
prostate specific antigen; prostate specific membrane antigen;  
prostate acid phosphatase; mucin; lactadherin;  
teratocarcinoma derived growth factor; PSA; PSMA; PAP; CRIPTO-1.

Homo sapiens.

WO200006723-A1.

10-FEB-2000.

29-JUL-1999; 99WO-IL000417.

30-JUL-1998; 98IL-00125608.

(YEDA ) YEDA RES & DEV CO LTD.  
(BIOT-) BIO-TECHNOLOGY GEN CORP.

Bisenbach L, Carnon L, Tirosh B, Bar-Haim E, Paz A, Fridkin M;  
Fitzner-Ahtas C;

WPI; 2000-205463/18.

Tumour associated antigen peptides, especially derived from uroplakin,  
PT useful as vaccines to prevent or cure cancers including breast, bladder,  
PT prostate, pancreas, ovary, thyroid, colon and stomach.

Claim 17; Page 99; 113pp; English.

Tumour associated antigen peptides (TAA) may be used for the treatment,  
CC prevention and cure of cancer or cancer metastases. The cancer may be  
CC breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach, head  
CC or neck cancer or a carcinoma. The tumour associated antigens are

CC presentable to the immune system by HLA-A2 molecules and are generally  
 CC between 8 to 10 amino acids in length. The amino acids located at  
 CC positions 2 and 9 of the tumour associated antigens are the anchor  
 CC residues which participate in the binding to MHC class I molecules, more  
 CC specifically HLA-A2. More tumour associated antigens are described in  
 CC GENESBQ records AAY82806-Y82882. Those tumour associated antigens  
 CC described in records AAY82806-Y82824 and AAY82855-Y82869 are derived  
 CC from Uroplakin, such as Uroplakin II, Uroplakin Ia, Uroplakin III and  
 CC Uroplakin IB. Those described in records AAY82825-Y82829 are derived from  
 CC prostate specific antigen (PSA). Those described in records AAY82830-  
 CC Y82835 are derived from prostate specific membrane antigen (PSMA). Those  
 CC described in records Y82836-AAY82839 are derived from prostate acid  
 CC phosphatase (PAP). Those described in records AAY82840-Y82846 are derived  
 CC from lactadherin (BA-46). Those described in records AAY82847-Y82854 are  
 CC derived from Mucin and those described in records AAY82871-Y82882 are  
 CC derived from Teratocarcinoma derived growth factor (CRIPTO-1)

XX Sequence 9 AA;

Query Match 2.3%; Score 49; DB 3; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.7e+06; Mismatches 0; Gaps 0;

Matches 9; Conservative 0; Indels 0;

131 NLRRMWT 139

DB 1 NLRRMWT 9

ABG32319 standard; peptide; 9 AA.

ABG32319;

05-NOV-2002 (first entry)

HLA-A1/A2 associated immunogenic peptide from human MFG-E8.

Human; immunogen; epitope; HLA-A1; human leukocyte antigen; CTL;

cytotoxic T lymphocyte; cytotoxic; cancer; colorectal carcinoma;

ovarian carcinoma; lung carcinoma; prostate carcinoma; vaccine; tumour;

HLA-2; passive immunotherapy; MFG-E8; milk fat globule glycoprotein E8.

Homo sapiens.

MO200246416-A2.

13-JUN-2002.

04-DEC-2001; 2001MO-US047290.

04-DEC-2000; 2000US-0251022P.

20-DEC-2000; 2000US-0256824P.

(ARGO-) ARGONEX INC.

Ramakrishna V, Ross M, Philip R;

WPI; 2002-619021/66.

New immunogen useful as a vaccine for inducing cytotoxic T-lymphocyte.

and for diagnosing, preventing or treating cancer e.g. ovarian carcinoma.

Claim 1; Page 50; 60pp; English.

The invention relates to an immunogen comprising an isolated polypeptide  
 CC whose amino acid sequence comprises an epitopic peptide, does not include  
 CC MAGE 4 or MFG-E8 proteins, or consists of MAGE D protein or its  
 CC immunologically active fragment. Also included are a polynucleotide  
 CC encoding the immunogen or its complement, a vector comprising the  
 CC polynucleotide, a mammalian cell comprising the vector and expressing the  
 CC polynucleotide, a vaccine composition comprising the immunogen and an  
 CC antibody specific for the immunogen. The immunogen is useful for inducing

CC a cytotoxic T lymphocyte (CTL) in vitro that is specific for a tumour  
 CC cell expressing human leukocyte antigen (HLA)-A1 or A2. The immunogen is  
 CC useful for inducing a CTL response when administered to a subject. A  
 CC mammalian cell that can express the immunogen, is useful for inducing a  
 CC CTL response in vitro that is specific for a tumour cell expressing HLA-1  
 CC or HLA-2. The immunogen or cell is useful for inducing CTL for treating a  
 CC subject with cancer (carcinoma, preferably colorectal carcinoma, ovarian  
 CC carcinoma, lung carcinoma and prostate carcinoma). The immunogen is also  
 CC useful for screening and diagnostic agents, for gene screening in  
 CC patients afflicted with cancer, for screening a sample for the presence  
 CC of CTLs that specifically recognise the corresponding epitopes, as a  
 CC diagnostic tool to evaluate the efficacy of the immunotherapeutic  
 CC treatments, to prepare class I MHC (major histocompatibility class)  
 CC tetramers which are utilised in conjunction with flow cytometry to  
 CC quantitate the frequency of peptide-specific CTL that are present in a  
 CC samples of lymphocytes from an individual, and for stimulating the  
 CC production of antibodies for use in passive immunotherapy, for use as  
 CC diagnostic reagents, and for use as reagents in other processes such as  
 CC affinity chromatography. The present sequence is an immunogenic epitope  
 CC of the invention derived from human MFG-E8 (milk fat globule glycoprotein  
 CC E8

XX Sequence 9 AA;

Query Match 2.3%; Score 48; DB 5; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.7e+06; Mismatches 0; Gaps 0;

Matches 9; Conservative 0; Indels 0;

152 HEYLKAFKV 160

DB 1 HEYLKAFKV 9

AAY82843 standard; peptide; 9 AA.

AAY82843;

19-JUN-2000 (first entry)

Lactadherin (BA-46) peptide fragment (tumour associated antigen).

Tumour associated antigen peptide; TAA; cancer; carcinoma; treatment;

prevention; cure; anti-tumour vaccine; metastases; breast; bladder;

prostate; pancreas; ovary; thyroid; colon; stomach; carcinoma; uroplakin;

MHC Class I; HLA-A2; human; Major Histocompatibility Complex; uroplakin;

prostate specific antigen; prostate specific membrane antigen;

prostate acid phosphatase; mucin; lactadherin;

teratocarcinoma derived growth factor; PSA; PSMA; PAP; CRIPTO-1.

Homo sapiens.

MO200006723-A1.

10-FEB-2000.

29-JUL-1999; 99MO-II000417.

30-JUL-1998; 98IL-00125608.

(YEDA ) YEDA RES & DEV CO LTD.

(BIOT-) BIO-TECHNOLOGY GEN CORP.

Eisenbach L, Carmon L, Tirosh B, Bar-Haim E, Paz A, Fridkin M;

WPI; 2000-205463/18.

Tumour associated antigen peptides, especially derived from uroplakin,  
 CC useful as vaccines to prevent or cure cancers including breast, bladder,  
 CC prostate, pancreas, ovary, thyroid, colon and stomach.

PS Claim 17; Page 100; 113pp; English.

XX Tumour associated antigen peptides (TAA) may be used for the treatment,  
XX prevention and cure of cancer or cancer metastases. The cancer may be  
CC breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach, head  
CC or neck cancer or a carcinoma. The tumour associated antigens are  
CC presentable to the immune system by HLA-A2 molecules and are generally  
CC between 8 to 10 amino acids in length. The amino acids located at  
CC positions 2 and 9 of the tumour associated antigens are the anchor  
CC residues which participate in the binding to MHC class I molecules, more  
CC specifically HLA-A2. More tumour associated antigens are described in  
CC GENESEQ records AAY82806-Y82882. Those tumour associated antigens  
CC described in records AAY82806-Y82824 and AAY82855-Y82869 are derived  
CC from Uroplakin, such as Uroplakin II, Uroplakin Ia, Uroplakin III and  
CC Uroplakin IB. Those described in records AAY82825-Y82829 are derived from  
CC prostate specific antigen (PSA). Those described in records AAY82830-  
CC Y82835 are derived from prostate specific membrane antigen (PSMA). Those  
CC described in records Y82836-AAY82839 are derived from prostate acid  
CC phosphatase (PAP). Those described in records AAY82840-Y82846 are derived  
CC from lactadherin (BA-46). Those described in records AAY82847-Y82854 are  
CC derived from Mucin and those described in records AAY82871-Y82882 are  
CC derived from Teratocarcinoma derived growth factor (CRIPTO-1)

XX Sequence 9 AA;

Query Match 2.2%; Score 46; DB 3; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 194 NLEFTEVEA 202  
|||  
1 NLEFTEVEA 9

RESULT 6  
AAY82842  
ID AAY82842 standard; peptide; 9 AA.

XX AAY82842;

DT 19-JUN-2000 (first entry)

XX Lactadherin (BA-46) peptide fragment (tumour associated antigen).

XX Tumour associated antigen peptide; TAA; cancer; carcinoma; treatment;  
XX prevention; cure; anti-tumour vaccine; metastases; breast; bladder;  
XX prostate; pancreas; ovary; thyroid; colon; stomach; carcinoma;  
XX MHC Class I; HLA-A2; human; Major Histocompatibility Complex; uroplakin;  
XX prostate specific antigen; prostate specific membrane antigen;  
XX prostate acid phosphatase; mucin; lactadherin;  
XX teratocarcinoma derived growth factor; PSA; PSMA; PAP; CRIPTO-1.

XX Homo sapiens.

XX WO200006723-A1.

XX 10-FEB-2000.

XX 29-JUL-1999; 99WO-11000417.

XX 30-JUL-1998; 98IL-00125608.

XX (YEDA ) YEDA RES & DEV CO LTD.  
XX (BIOT-) BIO-TECHNOLOGY GEN CORP.

XX Eisenbach L, Carmon L, Tirosh B, Bar-Haim E, Paz A, Fridkin M,  
XX Fitzer-Atlas C;

XX MPI; 2000-205463/18.

XX Tumor associated antigen peptides, especially derived from uroplakin,  
XX useful as vaccines to prevent or cure cancers including breast, bladder,  
XX prostate, pancreas, ovary, thyroid, colon and stomach.

XX Claim 17; Page 99; 113pp; English.

XX Tumour associated antigen peptides (TAA) may be used for the treatment,  
XX prevention and cure of cancer or cancer metastases. The cancer may be  
CC breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach, head  
CC or neck cancer or a carcinoma. The tumour associated antigens are  
CC presentable to the immune system by HLA-A2 molecules and are generally  
CC between 8 to 10 amino acids in length. The amino acids located at  
CC positions 2 and 9 of the tumour associated antigens are the anchor  
CC residues which participate in the binding to MHC class I molecules, more  
CC specifically HLA-A2. More tumour associated antigens are described in  
CC GENESEQ records AAY82806-Y82882. Those tumour associated antigens  
CC described in records AAY82806-Y82824 and AAY82855-Y82869 are derived  
CC from Uroplakin, such as Uroplakin II, Uroplakin Ia, Uroplakin III and  
CC Uroplakin IB. Those described in records AAY82825-Y82829 are derived from  
CC prostate specific antigen (PSA). Those described in records AAY82830-  
CC Y82835 are derived from prostate specific membrane antigen (PSMA). Those  
CC described in records Y82836-AAY82839 are derived from prostate acid  
CC phosphatase (PAP). Those described in records AAY82840-Y82846 are derived  
CC from lactadherin (BA-46). Those described in records AAY82847-Y82854 are  
CC derived from Mucin and those described in records AAY82871-Y82882 are  
CC derived from Teratocarcinoma derived growth factor (CRIPTO-1)

XX Sequence 9 AA;

Query Match 2.1%; Score 45; DB 3; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.7e+06;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 356 NLEFTEPILA 364  
|||  
1 NLEFTEPILA 9

RESULT 7  
ABJ50137  
ID ABJ50137 standard; peptide; 10 AA.

XX ABJ50137;

DT 16-OCT-2003 (first entry)

XX 151P3D4 cancer gene related HLA peptide #7957.

XX Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;  
XX cellular immune response; adenocarcinoma; bladder; colorectal; lung;  
XX bronchial; breast; carcinoma; human leukocyte antigen; HLA.

XX Homo sapiens.

XX WO200283860-A2.

XX 24-OCT-2002.

XX 09-APR-2002; 2002WO-US011644.

XX 10-APR-2001; 2001US-0282739P.

XX 25-APR-2001; 2001US-0286630P.

XX (AGEN-) AGENSYS INC.

XX Chalilta-Eld PM, Raitano AB, Faris M, Hubert RS, Morrison K;  
XX Morrison RK, Ge W, Jakobovits A;

XX MPI; 2003-167091/16.

XX New 151P3D4 proteins and genes, useful for eliciting a humoral or  
XX cellular immune response, or for diagnosing, prognosing, preventing or  
XX treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer  
XX or carcinoma.

XX Claim 13; Page 235; 426pp; English.

XX The invention relates to a novel composition comprising a substance that  
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or  
CC a molecule that is modulated by the 151P3D4 protein, where the status of  
CC a cell that expresses the 151P3D4 protein is modulated. The novel  
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting  
CC a humoral or cellular immune response. The 151P3D4 genes and proteins  
CC are also useful for diagnosing, prognosing, preventing or treating  
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or  
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a  
CC human leukocyte antigen peptide relating to the 151P3D4 composition of  
CC the invention

SQ Sequence 10 AA;

Query Match 2.1%; Score 45; DB 6; Length 10;  
Best Local Similarity 90.0%; Pred. No. 9.3e+03;  
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 299 VTGIITQGAR 308  
DB 1 VTGIITQGAK 10

RESULT 8  
ABJ51815  
ID ABJ51815 standard; peptide; 10 AA.

AC ABJ51815;  
DT 16-OCT-2003 (first entry)

DE 151P3D4 cancer gene related HLA peptide #9635.

XX Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;  
XX cellular immune response; adenocarcinoma; bladder; colorectal; lung;  
XX bronchial; breast; carcinoma; human leukocyte antigen; HLA.

OS Homo sapiens.

PN WO200283860-A2.

PD 24-OCT-2002.

PF 09-APR-2002; 2002WO-US011644.

PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

XX (AGEN-) AGENSYS INC.

XX Challita-Elid PM, Raitano AB, Faris M, Hubert RS, Morrison K;  
PI Morrison RK, Ge W, Jakobovits A;

DR WPI; 2003-167091/16.

XX New 151P3D4 proteins and genes, useful for eliciting a humoral or  
PT cellular immune response, or for diagnosing, prognosing, preventing or  
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer  
PT or carcinoma.

PS Claim 13; Page 251; 426pp; English.

XX The invention relates to a novel composition comprising a substance that  
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or  
CC a molecule that is modulated by the 151P3D4 protein, where the status of  
CC a cell that expresses the 151P3D4 protein is modulated. The novel  
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting  
CC a humoral or cellular immune response. The 151P3D4 genes and proteins  
CC are also useful for diagnosing, prognosing, preventing or treating  
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or  
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a  
CC human leukocyte antigen peptide relating to the 151P3D4 composition of

CC the invention

XX Sequence 10 AA;

Query Match 2.1%; Score 45; DB 6; Length 10;  
Best Local Similarity 90.0%; Pred. No. 9.3e+03;  
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 299 VTGIITQGAR 308  
DB 1 VTGIITQGAK 10

RESULT 9  
ABJ40507  
ID ABJ40507 standard; peptide; 10 AA.

AC ABJ40507;

DT 17-OCT-2003 (first entry)

DE 151P3D4 cancer gene related peptide #1134.

XX Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;  
XX cellular immune response; adenocarcinoma; bladder; colorectal; lung;  
XX bronchial; breast; carcinoma.

OS Unidentified.

PN WO200283860-A2.

PD 24-OCT-2002.

PF 09-APR-2002; 2002WO-US011644.

PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

XX (AGEN-) AGENSYS INC.

XX Challita-Elid PM, Raitano AB, Faris M, Hubert RS, Morrison K;  
PI Morrison RK, Ge W, Jakobovits A;

DR WPI; 2003-167091/16.

XX New 151P3D4 proteins and genes, useful for eliciting a humoral or  
PT cellular immune response, or for diagnosing, prognosing, preventing or  
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer  
PT or carcinoma.

PS Claim 13; Page 138; 426pp; English.

XX The invention relates to a novel composition comprising a substance that  
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or  
CC a molecule that is modulated by the 151P3D4 protein, where the status of  
CC a cell that expresses the 151P3D4 protein is modulated. The novel  
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting  
CC a humoral or cellular immune response. The 151P3D4 genes and proteins  
CC are also useful for diagnosing, prognosing, preventing or treating  
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or  
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a  
CC 151P3D4 related peptide of the invention

SQ Sequence 10 AA;

Query Match 2.1%; Score 45; DB 6; Length 10;  
Best Local Similarity 90.0%; Pred. No. 9.3e+03;  
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 299 VTGIITQGAR 308  
DB 1 VTGIITQGAK 10

RESULT 10  
ABJ39695  
ID ABJ39695 standard; peptide; 10 AA.  
XX  
AC ABJ39695;  
XX  
DT 17-OCT-2003 (first entry)  
XX  
DE 151P3D4 cancer gene related peptide #322.  
XX  
XX Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;  
XX cellular immune response; adenocarcinoma; bladder; colorectal; lung;  
XX bronchial; breast; carcinoma.  
OS Unidentified.  
XX  
PN WO200283860-A2.  
XX  
PD 24-OCT-2002.  
XX  
PF 09-APR-2002; 2002WO-US011644.  
XX  
PR 10-APR-2001; 2001US-0282739P.  
XX  
PR 25-APR-2001; 2001US-0286630P.  
XX  
XX (AGEN-) AGENSYS INC.  
PA  
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;  
PI Morrison RK, Ge W, Jakobovits A;  
XX  
DR MPI; 2003-167091/16.  
XX  
XX New 151P3D4 proteins and genes, useful for eliciting a humoral or  
PT cellular immune response, or for diagnosing, prognosing, preventing or  
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer  
PT or carcinoma.  
XX  
PS Claim 13; Page 130; 426pp; English.  
XX  
XX The invention relates to a novel composition comprising a substance that  
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or  
CC a molecule that is modulated by the 151P3D4 protein, where the status of  
CC a cell that expresses the 151P3D4 protein is modulated. The novel  
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting  
CC a humoral or cellular immune response. The 151P3D4 genes and proteins  
CC are also useful for diagnosing, prognosing, preventing or treating  
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or  
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a  
CC 151P3D4 related peptide of the invention  
CC  
SO Sequence 10 AA;  
Query Match 2.1%; Score 45; DB 6; Length 10;  
Best Local Similarity 90.0%; Pred. No. 9.3e+03;  
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 299 VTGIITOGAR 308  
DB 1 VTGIITOGAK 10  
RESULT 11  
ABJ54131  
ID ABJ54131 standard; peptide; 10 AA.  
XX  
AC ABJ54131;  
XX  
DT 16-OCT-2003 (first entry)  
XX  
DE 151P3D4 cancer gene related HLA peptide #11951.  
XX  
XX Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;

KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;  
XX bronchial; breast; carcinoma; human leukocyte antigen; HLA.  
XX  
OS Homo sapiens.  
XX  
PN WO200283860-A2.  
XX  
PD 24-OCT-2002.  
XX  
PF 09-APR-2002; 2002WO-US011644.  
XX  
PR 10-APR-2001; 2001US-0282739P.  
XX  
PR 25-APR-2001; 2001US-0286630P.  
XX  
XX (AGEN-) AGENSYS INC.  
PA  
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;  
PI Morrison RK, Ge W, Jakobovits A;  
XX  
DR MPI; 2003-167091/16.  
XX  
XX New 151P3D4 proteins and genes, useful for eliciting a humoral or  
PT cellular immune response, or for diagnosing, prognosing, preventing or  
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer  
PT or carcinoma.  
XX  
PS Claim 13; Page 273; 426pp; English.  
XX  
XX The invention relates to a novel composition comprising a substance that  
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or  
CC a molecule that is modulated by the 151P3D4 protein, where the status of  
CC a cell that expresses the 151P3D4 protein is modulated. The novel  
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting  
CC a humoral or cellular immune response. The 151P3D4 genes and proteins  
CC are also useful for diagnosing, prognosing, preventing or treating  
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or  
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a  
CC human leukocyte antigen peptide relating to the 151P3D4 composition of  
CC the invention  
CC  
SO Sequence 10 AA;  
Query Match 2.1%; Score 45; DB 6; Length 10;  
Best Local Similarity 90.0%; Pred. No. 9.3e+03;  
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 299 VTGIITOGAR 308  
DB 1 VTGIITOGAK 10  
RESULT 12  
ABJ40876  
ID ABJ40876 standard; peptide; 10 AA.  
XX  
AC ABJ40876;  
XX  
DT 17-OCT-2003 (first entry)  
XX  
DE 151P3D4 cancer gene related peptide #1503.  
XX  
XX Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;  
XX cellular immune response; adenocarcinoma; bladder; colorectal; lung;  
XX bronchial; breast; carcinoma.  
OS Unidentified.  
XX  
PN WO200283860-A2.  
XX  
PD 24-OCT-2002.  
XX  
PF 09-APR-2002; 2002WO-US011644.  
XX

PR 10-APR-2001; 2001US-0282739P.  
PR 25-APR-2001; 2001US-0286630P.  
XX (AGEN-) AGENSYS INC.  
XX  
XX Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;  
PI Morrison RK, Ge W, Jakobovits A;  
XX  
XX WPI; 2003-167091/16.  
XX  
XX New 151P3D4 proteins and genes, useful for eliciting a humoral or  
PT cellular immune response, or for diagnosing, prognosing, preventing or  
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer  
XX or carcinoma.  
XX  
XX Claim 13; Page 142; 426pp; English.  
XX  
XX The invention relates to a novel composition comprising a substance that  
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or  
CC a molecule that is modulated by the 151P3D4 protein, where the status of  
CC a cell that expresses the 151P3D4 protein is modulated. The novel  
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting  
CC a humoral or cellular immune response. The 151P3D4 genes and proteins  
CC are also useful for diagnosing, prognosing, preventing or treating  
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or  
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a  
CC 151P3D4 related peptide of the invention  
XX  
XX Sequence 10 AA;  
SQ  
Query Match 2.1%; Score 45; DB 6; Length 10;  
Best Local Similarity 90.0%; Pred. No. 9.3e+03;  
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 299 VTGIITQGAR 308  
DB 1 VTGIITQGAR 10  
RESULT 13  
ABJ53401  
ID ABJ53401 standard; peptide; 10 AA.  
XX  
XX ABJ53401;  
AC  
XX  
XX 16-OCT-2003 (first entry)  
DT  
XX  
XX 151P3D4 cancer gene related HLA peptide #11221.  
DE  
XX  
XX Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;  
KM cellular immune response; adenocarcinoma; bladder; colorectal; lung;  
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200283860-A2.  
PN  
XX  
XX 24-OCT-2002.  
PD  
XX  
XX 09-APR-2002; 2002WO-US011644.  
PF  
XX  
XX 10-APR-2001; 2001US-0282739P.  
PR 25-APR-2001; 2001US-0286630P.  
XX  
XX (AGEN-) AGENSYS INC.  
PA  
XX  
XX Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;  
PI Morrison RK, Ge W, Jakobovits A;  
XX  
XX WPI; 2003-167091/16.  
XX  
XX New 151P3D4 proteins and genes, useful for eliciting a humoral or  
PT cellular immune response, or for diagnosing, prognosing, preventing or

PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer  
XX or carcinoma.  
XX  
XX Claim 13; Page 266; 426pp; English.  
XX  
XX The invention relates to a novel composition comprising a substance that  
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or  
CC a molecule that is modulated by the 151P3D4 protein, where the status of  
CC a cell that expresses the 151P3D4 protein is modulated. The novel  
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting  
CC a humoral or cellular immune response. The 151P3D4 genes and proteins  
CC are also useful for diagnosing, prognosing, preventing or treating  
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or  
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a  
CC human leukocyte antigen peptide relating to the 151P3D4 composition of  
CC the invention  
XX  
XX Sequence 10 AA;  
SQ  
Query Match 2.1%; Score 45; DB 6; Length 10;  
Best Local Similarity 90.0%; Pred. No. 9.3e+03;  
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 299 VTGIITQGAR 308  
DB 1 VTGIITQGAR 10  
RESULT 14  
ABJ51353  
ID ABJ51353 standard; peptide; 10 AA.  
XX  
XX ABJ51353;  
AC  
XX  
XX 16-OCT-2003 (first entry)  
DT  
XX  
XX 151P3D4 cancer gene related HLA peptide #9173.  
DE  
XX  
XX Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;  
KM cellular immune response; adenocarcinoma; bladder; colorectal; lung;  
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200283860-A2.  
PN  
XX  
XX 24-OCT-2002.  
PD  
XX  
XX 09-APR-2002; 2002WO-US011644.  
PF  
XX  
XX 10-APR-2001; 2001US-0282739P.  
PR 25-APR-2001; 2001US-0286630P.  
XX  
XX (AGEN-) AGENSYS INC.  
PA  
XX  
XX Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;  
PI Morrison RK, Ge W, Jakobovits A;  
XX  
XX WPI; 2003-167091/16.  
XX  
XX New 151P3D4 proteins and genes, useful for eliciting a humoral or  
PT cellular immune response, or for diagnosing, prognosing, preventing or  
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer  
XX or carcinoma.  
XX  
XX Claim 13; Page 246; 426pp; English.  
XX  
XX The invention relates to a novel composition comprising a substance that  
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or  
CC a molecule that is modulated by the 151P3D4 protein, where the status of  
CC a cell that expresses the 151P3D4 protein is modulated. The novel  
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting  
CC a humoral or cellular immune response. The 151P3D4 genes and proteins

CC are also useful for diagnosing, prognosing, preventing or treating  
 CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or  
 CC bronchial cancer, breast cancer or carcinoma. This sequence represents a  
 CC human leukocyte antigen peptide relating to the 151P3D4 composition of  
 CC the invention  
 CC

XX  
 SQ Sequence 10 AA;

Query Match 2.1%; Score 45; DB 6; Length 10;  
 Best Local Similarity 90.0%; Pred. No. 9.3e+03;  
 Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 299 VTGIITOGAR 308  
 |||||  
 1 VTGIITOGAK 10

RESULT 15

ID ABJ52549 standard; peptide; 10 AA.

AC ABJ52549;

DT 16-OCT-2003 (first entry)

DE 151P3D4 cancer gene related HLA peptide #10369.

KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;  
 KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;  
 KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.

OS Homo sapiens.

PN WO200283860-A2.

PD 24-OCT-2002.

PF 09-APR-2002; 2002WO-US011644.

PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

PA (AGEN-) AGENSYS INC.

PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;  
 PI Morrison RK, Ge W, Jakobovits A;

DR WPI; 2003-167091/16.

PT New 151P3D4 proteins and genes, useful for eliciting a humoral or  
 PT cellular immune response, or for diagnosing, prognosing, preventing or  
 PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer  
 PT or carcinoma.

PS Claim 13; Page 258; 426pp; English.

XX The invention relates to a novel composition comprising a substance that  
 CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or  
 CC a molecule that is modulated by the 151P3D4 protein, where the status of  
 CC a cell that expresses the 151P3D4 protein is modulated. The novel  
 CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting  
 CC a humoral or cellular immune response. The 151P3D4 genes and proteins  
 CC are also useful for diagnosing, prognosing, preventing or treating  
 CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or  
 CC bronchial cancer, breast cancer or carcinoma. This sequence represents a  
 CC human leukocyte antigen peptide relating to the 151P3D4 composition of  
 CC the invention  
 CC

XX Sequence 10 AA;

Query Match 2.1%; Score 45; DB 6; Length 10;  
 Best Local Similarity 90.0%; Pred. No. 9.3e+03;  
 Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 299 VTGIITOGAR 308  
 |||||  
 1 VTGIITOGAK 10

Search completed: January 24, 2005, 14:42:22  
 Job time : 152 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OW protein - protein search, using sw model

Run on: January 24, 2005, 14:36:22 ; Search time 192 Seconds

(without alignments)  
1159.740 Million cell updates/sec

Title: US-09-744-804A-78

Sequence: 1 MRPRLALCGALCAPSL.....RLPVAMHNRILRLGLGC 387

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1825181 seqs, 575374646 residues

Total number of hits satisfying chosen parameters: 2971

Minimum DB seq length: 0  
Maximum DB seq length: 10

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database : UniProt\_02:\*  
1: uniprot\_sprot:\*  
2: uniprot\_trembl:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	31	1.5	9	2	012096
2	31	1.5	9	2	012098
3	31	1.5	9	2	012100
4	31	1.5	9	2	012102
5	31	1.5	9	2	012104
6	30	1.4	9	1	OXVA_SQUAC
7	29	1.4	10	2	07M4C2
8	28	1.3	8	1	LCK6_LEUMA
9	28	1.3	10	2	09GKT4
10	28	1.3	10	2	09GKT5
11	27	1.3	9	1	OXVA_SCYCA
12	27	1.3	9	2	07M4Q9
13	26	1.2	7	1	PAR2_ASCSU
14	26	1.2	8	1	PK2_PERAM
15	26	1.2	9	2	TAL1_PICJA
16	26	1.2	9	2	09R6T5
17	26	1.2	9	2	P90359
18	26	1.2	9	2	07ZRP3
19	26	1.2	10	2	09P2Z9
20	25	1.2	8	1	LCK4_LEUMA
21	25	1.2	8	1	LCK5_LEUMA
22	25	1.2	8	1	PK1_PERAM
23	25	1.2	8	1	PK5_PERAM
24	25	1.2	8	1	PK3_PERAM
25	25	1.2	8	2	PLP_BRANA
26	25	1.2	8	2	07M124
27	25	1.2	8	2	07LZ27
28	25	1.2	9	1	LITR_PHYRO
29	25	1.2	9	1	NEF_HV128
30	25	1.2	9	1	OXVF_SCYCA
31	25	1.2	9	1	TAL3_PICJA

32	25	1.2	9	2	AAP84334	AAP84334 human imm
33	25	1.2	10	1	GONI_CHEPR	P80677 cheyosoma
34	25	1.2	10	2	Q7M530	P80677 cheyosoma
35	25	1.2	10	2	09H3R9	09H3R9 homo sapien
36	25	1.2	10	2	035013	035013 meloidogyne
37	25	1.2	10	2	P96305	P96305 alteromonas
38	25	1.2	10	2	Q7WUG1	Q7WUG1 pseudomonas
39	25	1.2	10	2	P96423	P96423 pseudomonas
40	25	1.2	10	2	Q7DCH6	Q7DCH6 pseudomonas
41	25	1.2	10	2	Q765Y7	Q765Y7 gallus gall
42	25	1.2	10	2	BAD14908	BAD14908 gallus ga
43	24.5	1.2	8	1	LCK3_LEUMA	P21142 leucophaea
44	24	1.1	4	1	OCPI_OCTMI	P58649 octopus min
45	24	1.1	8	1	LCK1_LEUMA	P21140 leucophaea

## ALIGNMENTS

RESULT 1									
ID	012096	PRELIMINARY;	PRT;	9	AA.				
AC	012096;								
DT	01-JUL-1997 (TREMBLrel. 04, Created)								
DT	01-JUL-1997 (TREMBLrel. 04, Last sequence update)								
DT	01-DEC-2001 (TREMBLrel. 19, Last annotation update)								
DE	Tat protein (Fragment).								
GN	Name=tat;								
OS	Caprine arthritis encephalitis virus (CAEV).								
OC	Viruses; Retroid viruses; Retroviridae; Lentivirus.								
OX	NCBI_TaxID=11660;								
RN	[1]								
RP	SEQUENCE FROM N.A.								
RA	Turelli P., Guiguen F., Mornex J.-F., Vigne R., Querat G.;								
RL	Submitted (DEC-1996) to the EMBL/Genbank/DBJ databases.								
DR	EMBL; U81439; AAB60832.1; -.								
FT	NON TER	1							
SO	SEQUENCE	9	AA;	922	MM;	21E8644EB7340EB8	CRC64;		
Query Match									
Best Local Similarity 62.5%; Score 31; DB 2; Length 9;									
Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;									
Oy	11	CGALLCAP	18						
Db	1	CGCRICNP	8						
RESULT 2									
ID	012098	PRELIMINARY;	PRT;	9	AA.				
AC	012098;								
DT	01-JUL-1997 (TREMBLrel. 04, Created)								
DT	01-JUL-1997 (TREMBLrel. 04, Last sequence update)								
DT	01-DEC-2001 (TREMBLrel. 19, Last annotation update)								
DE	Tat protein (Fragment).								
GN	Name=tat;								
OS	Caprine arthritis encephalitis virus (CAEV).								
OC	Viruses; Retroid viruses; Retroviridae; Lentivirus.								
OX	NCBI_TaxID=11660;								
RN	[1]								
RP	SEQUENCE FROM N.A.								
RA	Turelli P., Guiguen F., Mornex J.-F., Vigne R., Querat G.;								
RL	Submitted (DEC-1996) to the EMBL/Genbank/DBJ databases.								
DR	EMBL; U81440; AAB60835.1; -.								
FT	NON TER	1							
SO	SEQUENCE	9	AA;	922	MM;	21E8644EB7340EB8	CRC64;		
Query Match									
Best Local Similarity 62.5%; Score 31; DB 2; Length 9;									
Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;									
Oy	11	CGALLCAP	18						

Db 1 CGCRLCNP 8

## RESULT 3

012100  
ID 012100; PRELIMINARY; PRT; 9 AA.  
AC 012100; (TREMBlrel. 04, Created)  
DT 01-JUL-1997 (TREMBlrel. 04, Last sequence update)  
DR 01-DEC-2001 (TREMBlrel. 19, Last annotation update)  
DE Rat protein (Fragment).  
GN Name=rat;  
OS Caprine arthritis encephalitis virus (CAEV).  
OC Viruses; Retrovirda; Retroviridae; Lentivirus.  
NCBI\_TaxID=11660;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Turelli P., Guiguen F., Mornex J.-F., Vigne R., Querat G.;  
RL Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.  
DR EMBL; U81441; AAB60836.1; -.  
FT NON TER 1  
SQ SEQUENCE 9 AA; 922 MW; 21E8644EB7340EB8 CRC64;  
Query Match 1.5%; Score 31; DB 2; Length 9;  
Best Local Similarity 62.5%; Pred. No. 1.8e+06;  
Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 11 CGALLCAP 18  
Db 1 CGCRLCNP 8

## RESULT 4

012102  
ID 012102; PRELIMINARY; PRT; 9 AA.  
AC 012102;  
DT 01-JUL-1997 (TREMBlrel. 04, Created)  
DR 01-JUL-1997 (TREMBlrel. 04, Last sequence update)  
DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)  
DE Rat protein (Fragment).  
GN Name=rat;  
OS Caprine arthritis encephalitis virus (CAEV).  
OC Viruses; Retrovirda; Retroviridae; Lentivirus.  
NCBI\_TaxID=11660;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Turelli P., Guiguen F., Mornex J.-F., Vigne R., Querat G.;  
RL Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.  
DR EMBL; U81442; AAB60838.1; -.  
FT NON TER 1  
SQ SEQUENCE 9 AA; 922 MW; 21E8644EB7340EB8 CRC64;

Query Match 1.5%; Score 31; DB 2; Length 9;  
Best Local Similarity 62.5%; Pred. No. 1.8e+06;  
Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 11 CGALLCAP 18  
Db 1 CGCRLCNP 8

## RESULT 5

012104  
ID 012104; PRELIMINARY; PRT; 9 AA.  
AC 012104;  
DT 01-JUL-1997 (TREMBlrel. 04, Created)  
DR 01-JUL-1997 (TREMBlrel. 04, Last sequence update)  
DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)  
DE Tat protein (Fragment).  
GN Name=tat;  
OS Caprine arthritis encephalitis virus (CAEV).  
OC Viruses; Retrovirda; Retroviridae; Lentivirus.

OX NCBI\_TaxID=11660;

RN [1]  
RP SEQUENCE FROM N.A.  
RA Turelli P., Guiguen F., Mornex J.-F., Vigne R., Querat G.;  
RL Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.  
DR EMBL; U81443; AAB60840.1; -.  
FT NON TER 1  
SQ SEQUENCE 9 AA; 922 MW; 21E8644EB7340EB8 CRC64;

Query Match 1.5%; Score 31; DB 2; Length 9;  
Best Local Similarity 62.5%; Pred. No. 1.8e+06;  
Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 11 CGALLCAP 18  
Db 1 CGCRLCNP 8

## RESULT 6

OXVA SQUAC  
ID 012102; STANDARD; PRT; 9 AA.  
AC P42959;  
DT 01-NOV-1995 (Rel. 32, Created)  
DT 01-NOV-1995 (Rel. 32, Last sequence update)  
DT 05-JUL-2004 (Rel. 44, Last annotation update)  
DE Aspartocin (Aspartocin).  
OS Squalus acanthias (Squalus dogfish).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;  
OC Rasmobranchii; Squalae; Hypnosqualea; Squaliformes; Squaloidei;  
OC Squalidae; Squalus.  
NCBI\_TaxID=7797;  
RN [1]  
RP SEQUENCE.

RX MEDLINE=73031727; PubMed=5083097;  
RA Acher R., Chauvet J., Chauvet M.-T.;  
RT "Phylogeny of the neurohypophyseal hormones. Two new active peptides isolated from a cartilaginous fish, Squalus acanthias.";  
RL Eur. J. Biochem. 29:12-19 (1972).  
RN [2]  
RP SEQUENCE.

RX MEDLINE=72128038; PubMed=4622083;  
RA Acher R., Chauvet J., Chauvet M.-T., Fontaine M.;  
RT "Identification of 2 new neurohypophyseal hormones, valitocin (Val8-oxytocin) and aspartocin (Asn4-oxytocin) in a selachian fish, the spiny dog-fish (Squalus acanthias).";  
RL C. R. Acad. Sci., D, Sci. Nat. 274:313-316 (1972).  
CC -1- SUBCELLULAR LOCATION: Secreted.

CC -1- SIMILARITY: Belongs to the vasopressin/oxytocin family.  
DR InterPro: IPR000981; Neuhyp\_horm.

DR Pfam: PF00220; Hormone\_4; 1.  
DR PROSITE: PS00264; NEUROHYPOPHYS\_HORM; 1.  
KW Annotation: Direct protein sequencing; Hormone.

FT DISULFID 1  
FT MOD RES 9  
SQ SEQUENCE 9 AA; 996 MW; 17F8376BB444404B CRC64;

Query Match 1.4%; Score 30; DB 1; Length 9;  
Best Local Similarity 54.5%; Pred. No. 1.8e+06;  
Matches 6; Conservative 1; Mismatches 2; Indels 2; Gaps 1;

QY 225 CEANGCANPG 235  
Db 1 CYINNC--PLG 9

## RESULT 7

07M4C2  
ID 07M4C2; PRELIMINARY; PRT; 10 AA.  
AC 07M4C2;  
DT 01-MAR-2004 (TREMBlrel. 26, Created)  
DT 01-MAR-2004 (TREMBlrel. 26, Last sequence update)  
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)  
DE Sperm-activating peptide (Tyr-2, Asn-3, Asp-7,10, Arg-8, Ile-9 SAP-

DE 1).  
 OS Echinometra mathaei (Rock boring urchin).  
 OC Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Echinozoa;  
 OC Echinoides; Echinoidea; Echinacea; Echinoida; Echinometridae;  
 OC Echinometra; Echinometra; Echinometra; Echinometra;  
 NCBI\_TaxID=31178;  
 RN [1]  
 RP SEQUENCE.  
 RA Yoshino K.I., Kajiyama H., Nomura K., Takao T., Shimonishi Y.,  
 RA Kurita M., Yamaguchi M., Suzuki N.;  
 RT "A halogenated amino acid-containing sperm activating peptide and its  
 RT related peptides isolated from the egg jelly of sea urchins,  
 RT tripterygius gracilis, pseudoboleia maculata, Strongylocentrotus  
 RT nudus, Echinometra mathaei and Heterocentrotus mammillatus.";  
 RL Comp. Biochem. Physiol. 94:739-751(1989).  
 DR PIR, G60589; G60589.  
 SQ SEQUENCE 10 AA; 1136 MW; 128ADFOA8744724 CRC64;

Query Match 1.4%; Score 29; DB 2; Length 10;  
 Best Local Similarity 55.6%; Pred. No. 6.7e+04;  
 Matches 5; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 162 YSLNGHEPD 170  
 Db 2 YNLNGDRID 10

RESULT 8  
 LCK6\_LEUMA STANDARD; PRT; 8 AA.

AC P19988;  
 DT 01-FEB-1991 (Rel. 17, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 05-JUL-2004 (Rel. 44, Last annotation update)  
 DE Leucokinin VI (L-VI).  
 OS Leucophaea maderae (Madeira cockroach).  
 OC Eukaryota; Metazoa; Arthropoda; Insecta; Pterygota;  
 OC Blaberidae; Leucophaea.  
 NCBI\_TaxID=6988;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Head;  
 RX MEDLINE=87052651; PubMed=2877794;  
 RA Holman G.M., Cook B.J., Nachman R.J.;  
 RT "Isolation, primary structure, and synthesis of leucokinin V and VI:  
 RT myotropic peptides of leucophaea maderae.";  
 RL Comp. Biochem. Physiol. 88C:27-30(1987).  
 CC -1- FUNCTION: This cephalomyotropic peptide stimulates contractile  
 CC activity of cockroach proctodeum (hindgut).  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 DR PIR, US0316; US0316.  
 KW Amidation; Direct protein sequencing; Neuropeptide;  
 KM Pyroglutamate carboxylic acid.  
 FT MOD\_RES 1 1 Glycine amide.  
 FT MOD\_RES 8 8 Glycine amide.  
 SQ SEQUENCE 8 AA; 935 MW; 9D635B1B9D5A5A6 CRC64;

Query Match 1.3%; Score 28; DB 1; Length 8;  
 Best Local Similarity 57.1%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 250 SSYKTWG 256  
 Db 2 SSFHSWG 8

RESULT 9  
 O9GKI4 PRELIMINARY; PRT; 10 AA.  
 AC O9GKI4;  
 DT 01-MAR-2001 (T-EMBLrel. 16, Created)  
 DT 01-MAR-2001 (T-EMBLrel. 16, Last sequence update)

DT 01-DEC-2001 (T-EMBLrel. 19, Last annotation update)  
 DE Fragile X mental retardation 1 protein (Fragment).  
 GN Name=Fmr1;  
 OS Macaca arctoides (Stump-tailed macaque).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Cercopitheciidae;  
 OC Cercopitheciinae; Macaca.  
 NCBI\_TaxID=9540;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=21264938; PubMed=11058604;  
 RA Kumari D., Usdin K.;  
 RT "Interaction of the transcription factors USF1, USF2, and alpha -  
 RT Pal/Nrf-1 with the FMR1 promoter. Implications for Fragile X mental  
 RT retardation syndrome.";  
 RL J. Biol. Chem. 276:4357-4364(2001).  
 DR EMBL, AF251350; AAC44599.1; -.  
 FT NON\_TER 10  
 SQ SEQUENCE 10 AA; 1160 MW; 7C2A2BCB02D2C72B CRC64;

Query Match 1.3%; Score 28; DB 2; Length 10;  
 Best Local Similarity 66.7%; Pred. No. 8.1e+04;  
 Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 39 EEISOEVVG 47  
 Db 2 EEIIVEVVG 10

RESULT 10  
 O9GKI5 PRELIMINARY; PRT; 10 AA.  
 AC O9GKI5;  
 DT 01-MAR-2001 (T-EMBLrel. 16, Created)  
 DT 01-MAR-2001 (T-EMBLrel. 16, Last sequence update)  
 DT 01-DEC-2001 (T-EMBLrel. 19, Last annotation update)  
 DE Fragile X mental retardation 1 protein (Fragment).  
 GN Name=Fmr1;  
 OS Pan troglodytes (Chimpanzee).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.  
 NCBI\_TaxID=9598;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=21264938; PubMed=11058604;  
 RA Kumari D., Usdin K.;  
 RT "Interaction of the transcription factors USF1, USF2, and alpha -  
 RT Pal/Nrf-1 with the FMR1 promoter. Implications for Fragile X mental  
 RT retardation syndrome.";  
 RL J. Biol. Chem. 276:4357-4364(2001).  
 DR EMBL, AF251349; AAC44598.1; -.  
 FT NON\_TER 10  
 SQ SEQUENCE 10 AA; 1160 MW; 7C2A2BCB02D2C72B CRC64;

Query Match 1.3%; Score 28; DB 2; Length 10;  
 Best Local Similarity 66.7%; Pred. No. 8.1e+04;  
 Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 39 EEISOEVVG 47  
 Db 2 EEIIVEVVG 10

RESULT 11  
 OXVA\_SCYCA STANDARD; PRT; 9 AA.  
 ID OXVA\_SCYCA  
 AC P42936;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 05-JUL-2004 (Rel. 44, Last annotation update)  
 DE Aavacocin.  
 OS Scylliorhynchus canicula (Spotted dogfish) (Spotted catshark).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;

OC Elasmobranchii; Galeomorphii; Galeoidea; Carcharhiniformes;  
 OC Scyllorhinidae; Scyllorhinus.  
 OC NCBI\_TaxId=7830;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Plutitary;  
 RX MEDLINE=95062247; PubMed=7972045;  
 RA Chauvet J., Rouille Y., Chauvet M.-T., Acher R.;  
 RT "Special evolution of neurohypophyseal hormones in cartilaginous  
 fishes: aspartic acid and phasvotocin, two oxytocin-like peptides isolated  
 from the spotted dogfish (Scyllorhinus caniculus).";  
 RL Proc. Natl. Acad. Sci. U.S.A. 91:11266-11270(1994).  
 CC -1- FUNCTION: Displays oxytocic activity on rat uterus.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- SIMILARITY: Belongs to the vasopressin/oxytocin family.  
 DR InterPro: IPR000981; Neurohyp. horm.  
 DR Pfam: PF002220; Hormone\_4; 1.  
 DR PROSITE: PS00264; NEUROHYPOPHYS. HORM.; 1.  
 KW Amidation; Direct protein sequencing; Hormone.  
 FT DISULFID 1  
 FT MOD RES 9 9  
 SQ SEQUENCE 9 AA; 982 MW; 17EDD76BB44404B CRC64;  
 Query Match 1.3%; Score 27; DB 1; Length 9;  
 Best Local Similarity 45.5%; Pred. No. 1.8e+06;  
 Matches 5; Conservative 2; Mismatches 2; Indels 2; Gaps 1;  
 Oy 225 CEINGANPLIG 235  
 Db 1 CYINNC-PVG 9  
 RESULT 12  
 Q7M409 PRELIMINARY; PRT; 9 AA.  
 AC Q7M409;  
 DT 01-MAR-2004 (TREMBLrel. 26, Created)  
 DT 01-MAR-2004 (TREMBLrel. 26, Last sequence update)  
 DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)  
 DE Octamer-binding protein, Ku-like, 83K chain (Fragment).  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 OC NCBI\_TaxId=9606;  
 RN [1]  
 RP SEQUENCE.  
 RX MEDLINE=91131605; PubMed=1993678;  
 RA May G., Sutton C., Gould H.;  
 RT "Purification and characterization of Ku-2, an octamer-binding protein  
 related to the autoantigen Ku.";  
 RL J. Biol. Chem. 266:3052-3059(1991).  
 DR PIR; B39504; B39504.  
 FT NON\_TER 9 9  
 SQ SEQUENCE 9 AA; 1096 MW; C65D4AAB144699D2 CRC64;  
 Query Match 1.3%; Score 27; DB 2; Length 9;  
 Best Local Similarity 80.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 Oy 122 NDDNP 126  
 Db 5 NEDNP 9  
 RESULT 13  
 FAR2\_ASCSU STANDARD; PRT; 7 AA.  
 AC P31890;  
 DT 01-JUL-1993 (Rel. 26, Created)  
 DT 01-JUL-1993 (Rel. 26, Last sequence update)  
 DT 05-JUL-2004 (Rel. 44, Last annotation update)  
 DE FMRamide-like neuropeptide AF2.  
 OS Ascaris suum (Pig roundworm) (Ascaris lumbricoides), and

OS Panagrellus redivivus.  
 OC Eukaryota; Metazoa; Nematoda; Chromadorea; Ascaridida; Ascaridoidea;  
 OC Ascarididae; Ascaris.  
 OC NCBI\_TaxId=6253, 6233;  
 RN [1]  
 RP SEQUENCE.  
 RC SPECIES=A.suum;  
 RX MEDLINE=93324431; PubMed=8332542;  
 RA Cowden C., Stretton A.O.W.;  
 RT "AF2, an Ascaris neuropeptide: isolation, sequence, and bioactivity.";  
 RL Peptides 14:423-430(1993).  
 RN [2]  
 RP SEQUENCE.  
 RC SPECIES=P.redivivus;  
 RX MEDLINE=95060998; PubMed=7970891;  
 RA Maule A.G., Shaw C., Bowman J.W.;  
 RT "The FMRamide-like neuropeptide AF2 (Ascaris suum) is present in the  
 free-living nematode, Panagrellus redivivus (Nematoda, Rhabditida).";  
 RL Parasitology 109:351-356(1994).  
 CC -1- FUNCTION: Has effects on muscle tension.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- TISSUE SPECIFICITY: Found in the nerve cords and a variety of  
 ganglia particularly in the anterior regions.  
 CC -1- SIMILARITY: Belongs to the FARP (FMRamide related peptide)  
 family.  
 KW Amidation; Direct protein sequencing; Neuropeptide.  
 FT MOD RES 7 7  
 SQ SEQUENCE 7 AA; 992 MW; 69D4073B5B1E350 CRC64;  
 Query Match 1.2%; Score 26; DB 1; Length 7;  
 Best Local Similarity 80.0%; Pred. No. 1.8e+06;  
 Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 Oy 152 HEXLK 156  
 Db 2 HEYLR 6  
 RESULT 14  
 PK2\_PERAM STANDARD; PRT; 8 AA.  
 AC P62686;  
 DT 05-JUL-2004 (Rel. 44, Created)  
 DT 05-JUL-2004 (Rel. 44, Last sequence update)  
 DT 05-JUL-2004 (Rel. 44, Last annotation update)  
 DE Kinin-2 (Pea-K-2).  
 OS Periplaneta americana (American cockroach).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattellidae;  
 OC NCBI\_TaxId=6978;  
 RN [1]  
 RP SEQUENCE. FUNCTION, MASS SPECTROMETRY, AND AMIDATION.  
 RC TISSUE=Corpora cardiaca;  
 RX MEDLINE=98010462; PubMed=9350979;  
 RA Predel R., Kellner R., Rapus J., Penzlin H., Gade G.;  
 RT "Isolation and structural elucidation of eight kinins from the  
 retrocerebral complex of the American cockroach, Periplaneta  
 americana.";  
 RL Regul. Pept. 71:199-205(1997).  
 CC -1- FUNCTION: Mediates visceral muscle contractile activity (myotropic  
 activity).  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- MASS SPECTROMETRY: MW=855.04; METHOD=Electrospray; RANGE=1-8;  
 CC NOTE=Ref.1.  
 CC -1- SIMILARITY: Belongs to the kinin family.  
 KW Amidation; Direct protein sequencing; Neuropeptide.  
 FT MOD RES 8 8  
 SQ SEQUENCE 8 AA; 856 MW; DC6365A5B9D5BDA CRC64;  
 Query Match 1.2%; Score 26; DB 1; Length 8;  
 Best Local Similarity 42.9%; Pred. No. 1.8e+06;  
 Matches 3; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 250 SSYKTMG 256  
 :|:|:  
 DB 2 ASFSWG 8

## RESULT 15

TALL\_PICJA STANDARD; PRT; 9 AA.  
 ID P17470;  
 AC 01-AUG-1990 (Rel. 15, Created)  
 DT 01-AUG-1990 (Rel. 15, last sequence update)  
 DT 05-JUL-2004 (Rel. 44, last annotation update)  
 DE Transaldolase I (EC 2.2.1.2) (Fragment).  
 OS Pichia jadinii (Yeast) (Candida utilis).  
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;  
 OC Saccharomycetales; Saccharomycetaceae; Pichia.  
 OX NCBI\_TaxID=4903;  
 RN [1]  
 RP SEQUENCE.  
 RX MEDLINE=7110646; Pubmed=556924;  
 RA Sun S.C., Joris L., Teolac O.;  
 RT "Purification of crystallization of transaldolase isozyme I and  
 RT evidence for different genetic origin of isozymes I and III in Candida  
 RT utilis.";  
 RL Arch. Biochem. Biophys. 178:69-78(1977).  
 CC -1- FUNCTION: Transaldolase is important for the balance of  
 CC metabolites in the pentose-phosphate pathway.  
 CC -1- CATALYTIC ACTIVITY: Sedoheptulose 7-phosphate + D-glyceraldehyde  
 CC 3-phosphate = D-erythrose 4-phosphate + D-fructose 6-phosphate.  
 CC -1- PATHWAY: Pentose phosphate pathway; nonoxidative part.  
 CC -1- SIMILARITY: Belongs to the transaldolase family. Subfamily 1.  
 DR PIR: A12872; A12872.  
 DR InterPro: IPR001585; Transaldolase.  
 DR PROSITE: PS01054; TRANSALDOLASE\_1; PARTIAL.  
 DR PROSITE: PS00958; TRANSALDOLASE\_2; PARTIAL.  
 DR Direct protein sequencing; Pentose shunt; Transferase.  
 FT NON\_TER 1 9  
 FT NON\_TER 1 9  
 SQ SEQUENCE 9 AA, 1008 MW, 274F31AF0EB1E058 CRC64;

Query Match 1.24; Score 26; DB 1; Length 9;  
 Best Local Similarity 66.74; Pred. No. 1.8e+06;  
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 63 GNHGCT 68  
 :|:|:  
 DB 2 GHHCBT 7

Search completed: January 24, 2005, 14:39:44  
 Job time : 193 secs

**This Page Blank (uspto)**

**33 Junk (uspto)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using SW model

Run on: January 24, 2005, 14:36:23 ; Search time 39 Seconds  
(without alignments)  
954.766 Million cell updates/sec

Title: US-09-744-804a-78

Perfect score: 2110

Sequence: 1 MPRPRLIALCGALCAPSL.....RILPVAMHNRILRLGLC.387

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 1102

Minimum DB seq length: 0

Maximum DB seq length: 10

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database :  
1: p1r1:\*  
2: p1r2:\*  
3: p1r3:\*  
4: p1r4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	36	1.7	7	2	E48394 glycoprotein compo
2	33	1.6	7	2	B48394 major fat-globule
3	29	1.4	6	2	H48394 glycoprotein compo
4	29	1.4	10	2	G60589 sperm-activating p
5	28	1.3	8	2	JS0316 leucokinin VI - Ma
6	28	1.3	10	2	S65385 cytochrome-c oxida
7	27	1.3	9	2	B39504 octamer-binding pr
8	26	1.2	9	2	A12872 transaldolase (EC
9	26	1.2	10	2	FX0030 triacylglycerol li
10	25	1.2	5	2	JH0253 gut pentapeptide -
11	25	1.2	8	2	PT0691 T-cell receptor be
12	25	1.2	8	2	S19288 acylase - Kluyvera
13	25	1.2	8	2	JS0315 leucokinin V - Mad
14	25	1.2	8	2	A41117 acetylcholinestera
15	25	1.2	9	2	S07241 litorin - Rohde's
16	25	1.2	9	2	A11497 transaldolase (EC
17	25	1.2	10	2	PQ0753 beta-fructofuranos
18	25	1.2	10	2	A40753 aldehyde ferredoxi
19	24.5	1.2	9	2	A24244 adipokinetic hormo
20	24.5	1.2	9	2	PT0562 T-cell receptor be
21	24	1.1	7	2	PD0029 lev-kinin I - pena
22	24	1.1	8	2	A25836 L-serine ammonia-1
23	24	1.1	9	2	A93408 oxytocin - Austral
24	24	1.1	9	2	A92774 oxytocin - spotted
25	24	1.1	9	2	A93147 oxytocin - finback
26	24	1.1	9	2	A91466 oxytocin - hippo
27	24	1.1	9	2	B90667 oxytocin - rabbit
28	24	1.1	10	1	RHPSG gonadoliberin - pl
29	24	1.1	10	1	RHSHG gonadoliberin - sh

30	24	1.1	10	1	A61126 gonadoliberin - sp
31	24	1.1	10	1	RHAQ1 gonadoliberin I -
32	24	1.1	10	1	RHAQ2 gonadoliberin II -
33	24	1.1	10	2	B46030 gonadoliberin II -
34	24	1.1	10	2	A13587 caerulein-like pep
35	24	1.1	10	2	S59625 beta-galactosidase
36	24	1.1	10	2	S23370 T-cell receptor al
37	24	1.1	10	2	A46030 gonadoliberin I -
38	24	1.1	10	2	A21114 gonadoliberin I - ch
39	24	1.1	10	2	E60589 sperm-activating p
40	23.5	1.1	10	2	A31571 hypetrinhalosemic/
41	23.5	1.1	10	2	S71948 matrix metalloprot
42	23	1.1	6	2	JU0355 lipopeptide WS1279
43	23	1.1	6	2	PT0532 T-cell receptor be
44	23	1.1	6	2	PD0028 lev-kinin 2 - pena
45	23	1.1	7	2	B33882 cadmium-binding he

#### ALIGNMENTS

##### RESULT 1

E48394 glycoprotein component 16/major fat-globule membrane protein/MFG-E8 homolog - bovine (fr  
C/Species: Bos primigenius taurus (cattle)  
C/Date: 19-Nov-1993 #sequence\_revision 18-Nov-1994 #text\_change 07-Feb-1997  
C/Accession: E48394  
R/Mather, I.H.; Banghart, L.R.; Lane, W.S.  
Biochem. Mol. Biol. Int. 29, 545-554, 1993  
A/Title: The major fat-globule membrane proteins, bovine components 15/16 and guinea-pig  
II-like sequences.  
A/Reference number: A48394; MUID:93250576; PMID:8485470  
A/Accession: E48394  
A/Status: preliminary  
A/Molecule type: protein  
A/Residues: 1-7 <MAT>  
A/Experimental source: milk  
C/Keywode: glycoprotein

Query Match 1.7%; Score 36; DB 2; Length 7;  
Best Local Similarity 85.7%; Pred. No. 2.8e+05;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 101 WVEELAR 107  
DB 1 WAPELAR 7

##### RESULT 2

B48394 major fat-globule membrane protein GP 55 - guinea pig (fragment)  
C/Species: Cavia porcellus (guinea pig)  
C/Date: 19-Nov-1993 #sequence\_revision 18-Nov-1994 #text\_change 23-Mar-1995  
C/Accession: B48394  
R/Mather, I.H.; Banghart, L.R.; Lane, W.S.  
Biochem. Mol. Biol. Int. 29, 545-554, 1993  
A/Title: The major fat-globule membrane proteins, bovine components 15/16 and guinea-pig  
II-like sequences.  
A/Reference number: A48394; MUID:93250576; PMID:8485470  
A/Accession: B48394  
A/Status: preliminary  
A/Molecule type: protein  
A/Residues: 1-7 <MAT>  
A/Experimental source: milk  
C/Note: sequence extracted from NCBI backbone (NCBIP.131444)

Query Match 1.6%; Score 33; DB 2; Length 7;  
Best Local Similarity 85.7%; Pred. No. 2.8e+05;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 101 WVEELAR 107  
DB 1 WAPELAR 7

Db 1 WGPFLAR 7

# RESULT 3

H48394

glycoprotein component 16/major fat-globule membrane protein/MFG-E8 homolog - bovine (Fr

C:Species: Bos primigenius taurus (cattle)

C>Date: 19-Nov-1993 #sequence\_revision 18-Nov-1994 #text\_change 07-Feb-1997

C/Accession: H48394

R:Matner, I.H.; Baughart, L.R.; Lane, W.S.

Biochem. Mol. Biol. Int. 29, 545-554, 1993

A:Title: The major fat-globule membrane proteins, bovine components 15/16 and guinea-pig

II-like sequences.

A:Reference number: A48394; PMID:93250576; PMID:8485470

A/Accession: H48394

A>Status: preliminary

A:Molecule type: protein

A:Residues: 1-6 <MAT>

A:Experimental source: milk

A:Note: sequence extracted from NCBI backbone (NCBIP:131518)

C:Keywords: glycoprotein

## Query Match

Best Local Similarity 1.4%; Score 29; DB 2; Length 6;  
Pred. No. 2.8e+05;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 382 LELIGC 387

Db 1 VELLGC 6

# RESULT 4

G60589

sperm-activating peptide (Tyr-2, Asn-3, Asp-7,10, Arg-8, Ile-9 SAP-I) - Echinosmetra mach

C:Species: Echinosmetra machael

C>Date: 17-Apr-1993 #sequence\_revision 17-Apr-1993 #text\_change 16-Aug-2004

C/Accession: G60589

R:Yoshino, K.I.; Kajitara, H.; Nomura, K.; Takao, T.; Shimonishi, Y.; Kurita, M.; Yamaguc

Comp. Biochem. Physiol. B 94, 739-751, 1989

A:Title: A halogenated amino acid-containing sperm activating peptide and its related pe

ptus nudus; Echinosmetra machael and Heterocentrotus mammillatus.

A:Reference number: A60527

A/Accession: G60589

A:Molecule type: protein

A:Residues: 1-10 <YOS>

A:Cross-references: UNIPROT:Q7M4C2

## Query Match

Best Local Similarity 1.4%; Score 29; DB 2; Length 10;  
Pred. No. 1e+04;

Matches 5; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 162 YSLNGHEFD 170

Db 2 YNLNGRID 10

# RESULT 5

JS0316

leucokinin VI - Madeira cockroach

C:Species: Leucophaea madeira (Madeira cockroach)

C>Date: 07-Sep-1990 #sequence\_revision 07-Sep-1990 #text\_change 09-Jul-2004

C/Accession: JS0316

R:Holman, G.M.; Cook, B.J.; Nachman, R.J.

Comp. Biochem. Physiol. C 88, 27-30, 1987

A:Title: Isolation, primary structure, and synthesis of leucokinin V and VI: myotropic

A:Reference number: JS0315

A/Accession: JS0316

A:Molecule type: protein

A:Residues: 1-8 <HOL>

A:Cross-references: UNIPROT:P19988

C:Comment: Leucokinin, a family of cephalomyotropic peptides, stimulate contractile act

C:Keywords: amidated carboxyl end; cephalomyotropic peptide; pyroglutamic acid

F:1/Modified site: pyroglutamate carboxylic acid (Gln) #status experimental

F:8/Modified site: amidated carboxyl end (Gly) #status experimental

## Query Match

Best Local Similarity 1.3%; Score 28; DB 2; Length 8;  
Pred. No. 2.8e+05;

Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 250 SSYKWTWG 256

Db 2 SSFHSWG 8

# RESULT 6

S65385

Cytochrome-c oxidase (EC 1.9.3.1) chain VIIa, hepatic - rat (fragment)

C:Species: Rattus norvegicus (Norway rat)

C>Date: 12-Feb-1998 #sequence\_revision 20-Feb-1998 #text\_change 07-May-1999

C/Accession: S65385

R:Schaeffer, H.; Noack, H.; Halangk, W.; Brandt, U.; von Jagow, G.

Bur. J. Biochem. 230, 235-241, 1995

A:Title: Cytochrome-c oxidase in developing rat heart. Enzymic properties and amino-termi

A:Reference number: S65372; PMID:95324529; PMID:7601105

A/Accession: S65385

A>Status: preliminary

A:Molecule type: protein

A:Residues: 1-10 <SCH>

A:Keywords: oxidoreductase

## Query Match

Best Local Similarity 1.3%; Score 28; DB 2; Length 10;  
Pred. No. 1.2e+04;

Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 239 NSIPDKQ 245

Db 3 NKVPEKQ 9

# RESULT 7

B39504

octamer-binding protein, Ku-like, 83K chain - human (fragment)

C:Species: Homo sapiens (man)

C>Date: 30-Dec-1991 #sequence\_revision 30-Dec-1991 #text\_change 09-Jul-2004

C/Accession: B39504

R:May, G.; Sutton, C.; Gould, H.

J. Biol. Chem. 266, 3052-3059, 1991

A:Title: Purification and characterization of Ku-2, an octamer-binding protein related to

A:Reference number: A39504; PMID:9131605; PMID:1993678

A/Accession: B39504

A>Status: preliminary

A:Molecule type: protein

A:Residues: 1-9 <MAY>

A:Cross-references: UNIPROT:Q7M4Q9

## Query Match

Best Local Similarity 1.3%; Score 27; DB 2; Length 9;  
Pred. No. 2.8e+05;

Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 122 NDDNP 126

Db 5 NEDNP 9

# RESULT 8

A12872

transaldolase (EC 2.2.1.2) I - yeast (Pichia jadinii) (fragment)

C:Species: Pichia jadinii, Candida utilis

C>Date: 05-Jun-1987 #sequence\_revision 05-Jun-1987 #text\_change 09-Jul-2004

C/Accession: A12872

R:Sun, S.C.; Joris, L.; Tsolas, O.

Arch. Biochem. Biophys. 178, 69-78, 1977

A:Title: Purification and crystallization of transaldolase isozyme I and evidence for di

A:Reference number: A12872; PMID:77110646; PMID:556924

A/Accession: A12872

A:Molecule type: protein

A:Residues: 1-9 <SUN>  
A:Cross-references: UNIPROT:P17440  
C:Keywords: transferase

Query Match 1.2%; Score 26; DB 2; Length 9;  
Best Local Similarity 66.7%; Pred. No. 2.8e+05;  
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 63 GNNCET 68  
DB 2 GHHCBT 7

## RESULT 9

triacylglycerol lipase (EC 3.1.1.3) II - yeast (*Geotrichum candidum*) (fragments)  
C:Species: *Geotrichum candidum*  
C/Date: 31-Dec-1990 #sequence\_revision 31-Dec-1990 #text\_change 09-Jul-2004  
C/Accession: PX0030  
R:Sugihara, A.; Shimada, Y.; Tomlinage, Y.  
J. Biochem. 107, 426-430, 1990  
A:Title: Separation and characterization of two molecular forms of *Geotrichum candidum* 1  
A:Reference number: PX0030; MUID:90256718; PMID:2341377  
A:Accession: PX0030  
A:Molecule type: protein  
A:Residues: 1-10 <SUG>  
A:Cross-references: UNIPROT:P22394  
C:Comment: Lipase catalyzes the hydrolysis of triacylglycerols. This fungus contains two  
C:Keywords: carboxylic ester hydrolase

Query Match 1.2%; Score 26; DB 2; Length 10;  
Best Local Similarity 83.3%; Pred. No. 1.7e+04;  
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 PRPRLT 7  
DB 3 PRPRLT 8

## RESULT 10

gut pentapeptide - Japanese eel  
JH0253  
C:Species: *Anguilla japonica* (Japanese eel)  
C/Date: 31-Mar-1992 #sequence\_revision 31-Mar-1992 #text\_change 11-Apr-1995  
C/Accession: JH0253  
R:Wesaka, T.; Ikeda, T.; Kubota, I.; Muneoka, Y.; Ando, M.  
Biochem. Biophys. Res. Commun. 180, 828-832, 1991  
A:Title: Structure and function of a pentapeptide isolated from the gut of the eel.  
A:Reference number: JH0253; MUID:92062113; PMID:1953755  
A:Accession: JH0253  
A:Molecule type: protein  
A:Residues: 1-5 <UES>  
A:Experimental source: gut  
C:Comment: This peptide increased basal tone of the circular muscle of the esophagogastric  
and of the circular muscle of the gastro-intestinal junction.

Query Match 1.2%; Score 25; DB 2; Length 5;  
Best Local Similarity 80.0%; Pred. No. 2.8e+05;  
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 184 GNNMK 188  
DB 1 GNNMK 5

## RESULT 11

PT0691  
T-cell receptor beta chain V-D-J region (154-2K) - mouse (fragment)  
C:Species: *Mus musculus* (house mouse)  
C/Date: 17-Jul-1992 #sequence\_revision 17-Jul-1992 #text\_change 30-May-1997  
C/Accession: PT0691  
R:Feeney, A.J.  
J. Exp. Med. 174, 115-124, 1991

A:Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.  
A:Reference number: PT0509; MUID:91277601; PMID:1711558  
A:Accession: PT0691  
A:Status: translation not shown  
A:Molecule type: DNA  
A:Residues: 1-8 <FEE>  
A:Experimental source: day 18 fetal thymus, strain BALB/c  
C:Keywords: T-cell receptor

Query Match 1.2%; Score 25; DB 2; Length 8;  
Best Local Similarity 80.0%; Pred. No. 2.8e+05;  
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 335 DPRTG 339  
DB 4 EPRTG 8

## RESULT 12

acylase - *Kluyvera cryocrescens*  
S19288  
C:Species: *Kluyvera cryocrescens*  
C/Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 09-Jul-2004  
C/Accession: S19288  
R:Martin, J.; Slade, A.; Altken, A.; Arche, R.; Virden, R.  
Biochem. J. 280, 659-662, 1991  
A:Title: Chemical modification of serine at the active site of penicillin acylase from *Kluyvera cryocrescens*  
A:Reference number: S19288; MUID:92109664; PMID:1764029  
A:Accession: S19288  
A:Status: preliminary  
A:Molecule type: protein  
A:Residues: 1-8 <MAR>  
A:Cross-references: UNIPROT:Q7M124

Query Match 1.2%; Score 25; DB 2; Length 8;  
Best Local Similarity 80.0%; Pred. No. 2.8e+05;  
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 136 MWVTG 140  
DB 3 MWVTG 7

## RESULT 13

leucokinin V - Madeira cockroach  
JS0315  
C:Species: *Leucophaea maderae* (Madeira cockroach)  
C/Date: 07-Sep-1990 #sequence\_revision 07-Sep-1990 #text\_change 09-Jul-2004  
C/Accession: JS0315  
R:Holman, G.M.; Cook, B.J.; Nachman, R.J.  
Comp. Biochem. Physiol. C 88, 27-30, 1987  
A:Title: Isolation, primary structure, and synthesis of leucokinin V and VI: myotropic I  
A:Reference number: JS0315  
A:Accession: JS0315  
A:Molecule type: protein  
A:Residues: 1-8 <HOL>  
A:Cross-references: UNIPROT:P19987  
C:Comment: Leucokinin, a family of cephalomyotropic peptides, stimulate contractile acti  
C:Keywords: amidated carboxyl end; cephalomyotropic peptide  
F/8/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 1.2%; Score 25; DB 2; Length 8;  
Best Local Similarity 42.9%; Pred. No. 2.8e+05;  
Matches 3; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 250 SSYTWG 256  
DB 2 SSYTWG 8

## RESULT 14

A4117  
acetylcholinesterase (EC 3.1.1.7), venom - Asian cobra (fragment)

C;Species: Naja naja oxiata (Asian cobra, Oxus cobra)  
 C;Date: 27-Mar-1992 #sequence\_revision 27-Mar-1992 #text\_change 09-Jul-2004  
 C;Accession: A4117  
 R;Kreienkamp, H.J.; Weise, C.; Raba, R.; Aaviksaar, A.; Hucho, F.  
 Proc. Natl. Acad. Sci. U.S.A. 88, 6117-6121, 1991  
 A;Title: Anionic subsites of the catalytic center of acetylcholinesterase from Torpedo a  
 A;Reference number: A4117; MUID:91296772; PMID:2068091  
 A;Accession: A4117  
 A;Status: Preliminary  
 A;Molecule type: protein  
 A;Residues: 1-8 <KRE>  
 A;Cross-references: UNIPROT:Q7LZ27  
 C;Keywords: carboxylic ester hydrolase

Query Match 1.2%; Score 25; DB 2; Length 8;  
 Best Local Similarity 75.0%; Pred. No. 2.8e+05;  
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 262 WNP8 265  
 |||:  
 Db 5 WNP8 8

## RESULT 15

S07241  
 Iltorin - Rohde's leaf frog  
 C;Species: Phyllomedusa rohdei (Rohde's leaf frog)  
 C;Date: 12-Feb-1993 #sequence\_revision 12-Mar-1993 #text\_change 09-Jul-2004  
 C;Accession: S07241  
 R;Barra, D.; Falconieri Erspaner, G.; Simmaco, M.; Bossa, F.; Melchiorri, P.; Erspaner,  
 FEBS Lett. 182, 53-56, 1985  
 A;Title: Rohde's Iltorin: a new peptide from the skin of Phyllomedusa rohdei.  
 A;Reference number: S07241; MUID:85127560; PMID:3838283  
 A;Accession: S07241  
 A;Molecule type: protein  
 A;Residues: 1-9 <BAR>  
 A;Cross-references: UNIPROT:P08946  
 C;Superfamily: gastrin-releasing peptide  
 C;Keywords: amidated carboxyl end; blocked amino end; neuropeptide; pyroglutamic acid  
 F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
 F;9/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 1.2%; Score 25; DB 2; Length 9;  
 Best Local Similarity 50.0%; Pred. No. 2.8e+05;  
 Matches 3; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 135 RMWVG 140  
 ::|||  
 Db 1 QLMATG 6

Search completed: January 24, 2005, 14:46:21  
 Job time : 40 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 24, 2005, 14:36:22 ; Search time 142 Seconds  
(without alignments)  
984.641 Million cell updates/sec

Title: US-09-744-804A-78  
Perfect score: 2110  
Sequence: 1 MRPRLALCGALCAPSL.....RIPVAMHRIALRLLELGC 387

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1608061 seqs, 361289386 residues

Total number of hits satisfying chosen parameters: 184693

Minimum DB seq length: 0  
Maximum DB seq length: 10

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

1: Published Applications\_AA:\*  
2: /cgn2\_6/ptodata/1/pubppa/US07\_PUBCOMB.pep:\*  
3: /cgn2\_6/ptodata/1/pubppa/US06\_NEW\_PUB.pep:\*  
4: /cgn2\_6/ptodata/1/pubppa/US07\_NEW\_PUB.pep:\*  
5: /cgn2\_6/ptodata/1/pubppa/US07\_NEW\_PUB.pep:\*  
6: /cgn2\_6/ptodata/1/pubppa/US08\_NEW\_PUB.pep:\*  
7: /cgn2\_6/ptodata/1/pubppa/US08\_NEW\_PUB.pep:\*  
8: /cgn2\_6/ptodata/1/pubppa/US09\_PUBCOMB.pep:\*  
9: /cgn2\_6/ptodata/1/pubppa/US09\_PUBCOMB.pep:\*  
10: /cgn2\_6/ptodata/1/pubppa/US09\_PUBCOMB.pep:\*  
11: /cgn2\_6/ptodata/1/pubppa/US09\_PUBCOMB.pep:\*  
12: /cgn2\_6/ptodata/1/pubppa/US09\_PUBCOMB.pep:\*  
13: /cgn2\_6/ptodata/1/pubppa/US10\_PUBCOMB.pep:\*  
14: /cgn2\_6/ptodata/1/pubppa/US10\_PUBCOMB.pep:\*  
15: /cgn2\_6/ptodata/1/pubppa/US10\_PUBCOMB.pep:\*  
16: /cgn2\_6/ptodata/1/pubppa/US10\_PUBCOMB.pep:\*  
17: /cgn2\_6/ptodata/1/pubppa/US10\_NEW\_PUB.pep:\*  
18: /cgn2\_6/ptodata/1/pubppa/US11\_NEW\_PUB.pep:\*  
19: /cgn2\_6/ptodata/1/pubppa/US60\_NEW\_PUB.pep:\*  
20: /cgn2\_6/ptodata/1/pubppa/US60\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	48	2.3	9	14	US-10-006-177-19 Sequence 19, Appl
2	44	2.1	9	10	US-09-865-548A-43 Sequence 43, Appl
3	41	1.9	8	15	US-10-235-852-19 Sequence 19, Appl
4	39	1.8	8	9	US-09-908-322-88 Sequence 88, Appl
5	39	1.8	8	10	US-09-783-931-88 Sequence 88, Appl
6	35	1.7	9	16	US-10-743-649-6 Sequence 6, Appl
7	35	1.7	9	17	US-10-743-639-6 Sequence 6, Appl
8	35	1.7	10	10	US-09-572-404B-3564 Sequence 3564, Ap
9	34	1.6	8	9	US-09-947-925A-29 Sequence 29, Appl
10	34	1.6	9	14	US-10-083-768-69 Sequence 69, Appl
11	34	1.6	9	14	US-10-393-269-38 Sequence 38, Appl
12	34	1.6	9	17	US-10-774-176-16 Sequence 16, Appl
13	34	1.6	10	10	US-09-935-430-433 Sequence 433, Appl

14	34	1.6	10	10	US-09-809-638-585 Sequence 585, App
15	34	1.6	10	10	US-09-809-638-680 Sequence 680, App
16	34	1.6	10	10	US-09-563-223-34 Sequence 34, Appl
17	34	1.6	10	14	US-10-083-768-63 Sequence 63, Appl
18	34	1.6	10	14	US-10-277-292-433 Sequence 433, App
19	34	1.6	10	14	US-10-280-340-433 Sequence 433, App
20	34	1.6	10	15	US-10-609-217-46 Sequence 46, Appl
21	34	1.6	10	15	US-10-632-388-46 Sequence 46, Appl
22	34	1.6	10	15	US-10-651-723-46 Sequence 46, Appl
23	34	1.6	10	15	US-10-645-761-46 Sequence 46, Appl
24	34	1.6	10	15	US-10-666-696-46 Sequence 46, Appl
25	34	1.6	10	15	US-10-653-048-46 Sequence 46, Appl
26	34	1.6	10	17	US-10-783-950-34 Sequence 34, Appl
27	33	1.6	9	10	US-09-935-430-123 Sequence 123, App
28	33	1.6	9	10	US-09-935-430-216 Sequence 123, App
29	33	1.6	9	14	US-10-277-292-123 Sequence 123, App
30	33	1.6	9	14	US-10-277-292-216 Sequence 123, App
31	33	1.6	9	14	US-10-280-340-123 Sequence 123, App
32	33	1.6	9	14	US-10-280-340-216 Sequence 123, App
33	33	1.6	9	15	US-10-182-252A-190 Sequence 190, App
34	33	1.6	9	16	US-10-415-014-131 Sequence 331, App
35	33	1.6	10	10	US-09-572-404B-422 Sequence 422, App
36	33	1.6	10	10	US-09-572-404B-567 Sequence 567, App
37	33	1.6	10	10	US-09-572-404B-569 Sequence 569, App
38	33	1.6	10	10	US-09-572-404B-1017 Sequence 1017, Ap
39	33	1.6	10	14	US-10-083-768-122 Sequence 122, App
40	33	1.6	10	14	US-10-271-343-46 Sequence 46, Appl
41	33	1.6	10	16	US-10-440-479-6 Sequence 381, App
42	33	1.6	10	16	US-10-415-014-381 Sequence 1098, Ap
43	33	1.6	10	17	US-10-654-578-1098 Sequence 1370, Ap
44	33	1.6	10	17	US-10-654-578-1370 Sequence 1, Appl
45	32	1.5	7	15	US-10-442-880-1

#### ALIGNMENTS

RESULT 1  
US-10-006-177-19  
Sequence 19, Application US/10006177  
Publication No. US20030165513A1  
GENERAL INFORMATION:  
APPLICANT: Ramakrishna, Venky  
APPLICANT: Ross, Mark  
TITLE OF INVENTION: Philp, Ramla  
TITLE OF INVENTION: Cytotoxic T-Lymphocyte-Inducing Immunogens for Prevention, Treatme  
FILE REFERENCE: 26747-35  
CURRENT APPLICATION NUMBER: US/10/006,177  
CURRENT FILING DATE: 2001-12-04  
PRIOR APPLICATION NUMBER: US/60/251,022  
PRIOR FILING DATE: 2000-12-04  
PRIOR APPLICATION NUMBER: US/60/256,824  
PRIOR FILING DATE: 2000-12-20  
NUMBER OF SEQ ID NOS: 20  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 19  
LENGTH: 9  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Epitopic Peptide  
US-10-006-177-19

Query Match 2.3%; Score 48; DB 14; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.5e+06;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 152 HEYTKAFKV 160  
DB 1 HEYTKAFKV 9

RESULT 2  
US-09-865-548A-43  
Sequence 43, Application US/09865548A  
Publication No. US20030096298A1  
GENERAL INFORMATION:  
APPLICANT: Barnea, Eilon  
APPLICANT: Beer, Ilan  
APPLICANT: Ziv, Tamar  
APPLICANT: Admon, Arie  
TITLE OF INVENTION: METHOD OF IDENTIFYING PEPTIDES CAPABLE OF BINDING TO MHC MOLECULE  
TITLE OF INVENTION: PEPTIDES IDENTIFIED THEREBY AND THEIR USES  
FILE REFERENCE: 01/22080  
CURRENT APPLICATION NUMBER: US/09/865,548A  
CURRENT FILING DATE: 2001-05-16  
PRIOR APPLICATION NUMBER: US 60/290,958  
PRIOR FILING DATE: 2001-05-16  
NUMBER OF SEQ ID NOS: 204  
SOFTWARE: Patentin version 3.1  
SEQ ID NO 43  
LENGTH: 9  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: synthetic peptide  
US-09-865-548A-43

Query Match 2.1%; Score 44; DB 10; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.5e+06;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 ALLCAPSL 21  
DB 1 ALLCAPSL 9

RESULT 3  
US-10-235-852-19  
Sequence 19, Application US/10235852  
Publication No. US20040052928A1  
GENERAL INFORMATION:  
APPLICANT: Gazit, Ehud  
TITLE OF INVENTION: PEPTIDES AND METHODS USING SAME FOR DIAGNOSING AND TREATING AMYLO  
FILE REFERENCE: 02/23654  
CURRENT APPLICATION NUMBER: US/10/235,852  
CURRENT FILING DATE: 2002-09-06  
NUMBER OF SEQ ID NOS: 23  
SOFTWARE: Patentin version 3.1  
SEQ ID NO 19  
LENGTH: 8  
TYPE: PRT  
ORGANISM: Artificial sequence  
FEATURE:  
OTHER INFORMATION: lactadherin derived, active site sequence  
US-10-235-852-19

Query Match 1.9%; Score 41; DB 15; Length 8;  
Best Local Similarity 100.0%; Pred. No. 1.5e+06;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 309 NFGSVQFV 316  
DB 1 NFGSVQFV 8

RESULT 4  
US-09-908-322-88  
Sequence 88, Application US/09908322  
Patent No. US20020107194A1  
GENERAL INFORMATION:  
APPLICANT: Ish-Horowitz, David  
Henrique, Domingos Manuel Pinto  
Lewis, Julian Hart

Artavanis-Tsakonas, Spyridon  
Gray, Grace  
TITLE OF INVENTION: NUCLEOTIDE AND PROTEIN SEQUENCES OF  
VERTEBRATE DELTA GENE AND METHODS BASED THEREON  
NUMBER OF SEQUENCES: 94  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Pennie & Edmonds LLP  
STREET: 1155 Avenue of the Americas  
CITY: New York  
STATE: NY  
COUNTRY: USA  
ZIP: 10036/2711  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/908,322  
FILING DATE: 17-Jul-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/981,392  
FILING DATE: 22-DEC-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Mastrock, S Leslie  
REGISTRATION NUMBER: 18,872  
REFERENCE/DOCKET NUMBER: 7326-123  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-790-9090  
TELEFAX: 212-869-8864  
TELEX: 66141 PENNIS  
INFORMATION FOR SEQ ID NO: 88:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: unknown  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 88:  
US-09-908-322-88

Query Match 1.8%; Score 39; DB 9; Length 8;  
Best Local Similarity 85.7%; Pred. No. 1.5e+06;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 NPCHNG 36  
DB 1 NPCHNG 7

RESULT 5  
US-09-783-931-88  
Sequence 88, Application US/09783931  
Publication No. US20030073620A1  
GENERAL INFORMATION:  
APPLICANT: Ish-Horowitz, David  
Henrique, Domingos Manuel Pinto  
Lewis, Julian Hart  
Artavanis-Tsakonas, Spyridon  
Gray, Grace  
TITLE OF INVENTION: ANTIBODIES TO VERTEBRATE DELTA PROTEINS  
AND FRAGMENTS  
NUMBER OF SEQUENCES: 94  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Pennie & Edmonds LLP  
STREET: 1155 Avenue of the Americas  
CITY: New York  
STATE: NY  
COUNTRY: USA  
ZIP: 10036/2711  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/783,931  
FILING DATE: 15-Feb-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/981,392  
FILING DATE: 22-DEC-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Antler, Adriane M.  
REGISTRATION NUMBER: 32,605  
REFERENCE/DOCKET NUMBER: 7326-122  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-790-9090  
TELEFAX: 212-869-8864  
TELEX: 66141 PENNIE  
INFORMATION FOR SEQ ID NO: 88:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 8 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: unknown  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 88:  
US-09-783-931-88

Query Match 1.8%; Score 39; DB 10; Length 8;  
Best Local Similarity 85.7%; Pred. No. 1.5e+06;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 NPGCHG 36  
DB 1 NPGCHG 7

RESULT 6  
US-10-743-649-6  
Sequence 6, Application US/10743649  
Publication No. US20040170607A1  
GENERAL INFORMATION:  
APPLICANT: PRO-VIRUS, INC.  
TITLE OF INVENTION: ONCOLYTIC VIRUS  
FILE REFERENCE: 2370-63  
CURRENT APPLICATION NUMBER: US/10/743,649  
CURRENT FILING DATE: 2003-12-22  
PRIOR APPLICATION NUMBER: US/09/664,444  
PRIOR FILING DATE: 2000-09-18  
PRIOR APPLICATION NUMBER: 09/397,873  
PRIOR FILING DATE: 1999-09-17  
NUMBER OF SEQ ID NOS: 52  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 6  
LENGTH: 9  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
OTHER INFORMATION: peptide  
US-10-743-649-6

Query Match 1.7%; Score 35; DB 16; Length 9;  
Best Local Similarity 66.7%; Pred. No. 1.5e+06;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 348 WDNHSH 353  
DB 2 WDNHSH 7

RESULT 7  
US-10-743-639-6

Sequence 6, Application US/10743639  
Publication No. US20040208849A1  
GENERAL INFORMATION:  
APPLICANT: PRO-VIRUS, INC.  
TITLE OF INVENTION: ONCOLYTIC VIRUS  
FILE REFERENCE: 2370-63  
CURRENT APPLICATION NUMBER: US/10/743,639  
CURRENT FILING DATE: 2003-12-22  
PRIOR APPLICATION NUMBER: US/09/664,444  
PRIOR FILING DATE: 2000-09-18  
PRIOR APPLICATION NUMBER: 09/397,873  
PRIOR FILING DATE: 1999-09-17  
NUMBER OF SEQ ID NOS: 52  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 6  
LENGTH: 9  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
OTHER INFORMATION: peptide  
US-10-743-639-6

Query Match 1.7%; Score 35; DB 17; Length 9;  
Best Local Similarity 66.7%; Pred. No. 1.5e+06;  
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 348 WDNHSH 353  
DB 2 WDNHSH 7

RESULT 8  
US-09-572-404B-3564  
Sequence 3564, Application US/09572404B  
Publication No. US20030078374A1  
GENERAL INFORMATION:  
APPLICANT: Proteom Ltd  
TITLE OF INVENTION: Complementary peptide ligands from the human genome  
FILE REFERENCE: Human patent  
CURRENT APPLICATION NUMBER: US/09/572,404B  
CURRENT FILING DATE: 2000-05-17  
NUMBER OF SEQ ID NOS: 4203  
SOFTWARE: ProPatent version 1.0  
SEQ ID NO 3564  
LENGTH: 10  
TYPE: PRT  
ORGANISM: Homo Sapiens  
FEATURE:  
OTHER INFORMATION: sequence located in NID2 at 780-789 and may interact with Sequence  
US-09-572-404B-3564

Query Match 1.7%; Score 35; DB 10; Length 10;  
Best Local Similarity 83.3%; Pred. No. 1.4e+04;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 52 SYTCCTC 57  
DB 5 SYTCCTC 10

RESULT 9  
US-09-947-925A-29  
Sequence 29, Application US/09947925A  
Patent No. US20020055482A1  
GENERAL INFORMATION:  
APPLICANT: Huber, Brian  
APPLICANT: Richards, Cynthia  
TITLE OF INVENTION: Molecular Constructs Containing a Carcinoembryonic  
TITLE OF INVENTION: Antigen Regulatory  
FILE REFERENCE: PB1087US3

CURRENT APPLICATION NUMBER: US/09/947,925A  
CURRENT FILING DATE: 2001-09-06  
PRIOR APPLICATION NUMBER: US/08/154,712  
PRIOR FILING DATE: 1993-11-19  
NUMBER OF SEQ ID NOS: 36  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 29  
LENGTH: 8  
TYPE: PRT  
ORGANISM: Consensus sequence  
FEATURE:  
NAME/KEY: misc.feature  
OTHER INFORMATION: Consensus sequence f6 from transcriptional dictionary  
OTHER INFORMATION: of Locker a  
OTHER INFORMATION: nd Buzard (1990).  
US-09-947-925A-29

Query Match  
Best Local Similarity 71.4%; Score 34; DB 9; Length 8;  
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 211 SCTRACT 217  
:|||||  
1 TCONTACT 7

RESULT 10  
US-10-083-768-69  
Sequence 69, Application US/10083768  
Publication No. US20030158116A1  
GENERAL INFORMATION:  
APPLICANT: Dower, William J.  
Barrett, Ronald W.  
Cwirla, Steven E.  
Duffin, David J.  
Gates, Christian  
Haselden, Sherill S.  
Matheakis, Larry C.  
Schatz, Peter J.  
Wagstrom, Christopher R.  
Wrighton, Nicholas C.  
TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
THROMBOPOIETIN RECEPTOR  
NUMBER OF SEQUENCES: 232  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Glaxo Wellcome  
STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park  
STATE: NC  
COUNTRY: USA  
ZIP: 27709  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
Application Number: US/10/083,768  
Filing Date: 27-Feb-2002  
ATTORNEY/AGENT INFORMATION:  
NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PR3065USW  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000  
INFORMATION FOR SEQ ID NO: 69:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 9 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 69:

US-10-083-768-69

Query Match  
Best Local Similarity 46.7%; Score 34; DB 14; Length 9;  
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

QY 216 CTRPELLGCELNGC 230  
|||||  
1 CTRLEF-----MNGC 9

RESULT 11  
US-10-393-269-38  
Sequence 38, Application US/10393269  
Publication No. US20030223979A1  
GENERAL INFORMATION:  
APPLICANT: GELLERFORS, Par  
APPLICANT: ROGH, Jens  
TITLE OF INVENTION: NEW THERAPEUTIC METHOD FOR TREATING PATIENTS WITH ACUTE  
TITLE OF INVENTION: INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC  
DISEASES  
FILE REFERENCE: GELLERFORS-1A  
CURRENT APPLICATION NUMBER: US/10/393,269  
CURRENT FILING DATE: 2003-03-21  
PRIOR APPLICATION NUMBER: US/09/358,856C  
PRIOR FILING DATE: 1999-07-22  
NUMBER OF SEQ ID NOS: 40  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 38  
LENGTH: 9  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: encoded by  
US-10-393-269-38

Query Match  
Best Local Similarity 57.1%; Score 34; DB 14; Length 9;  
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 372 VAMHNR 378  
:|||||  
3 MGVHNRV 9

RESULT 12  
US-10-774-176-16  
Sequence 16, Application US/10774176  
Publication No. US20040265275A1  
GENERAL INFORMATION:  
APPLICANT: CARROLL, MILES WILLIAM  
APPLICANT: MYERS, KEVIN ALAN  
TITLE OF INVENTION: POLYPEPTIDE  
FILE REFERENCE: 078683/0120  
CURRENT APPLICATION NUMBER: US/10/774,176  
CURRENT FILING DATE: 2004-02-06  
PRIOR APPLICATION NUMBER: US/09/533,798  
PRIOR FILING DATE: 2000-03-24  
PRIOR APPLICATION NUMBER: 60/126,187  
PRIOR FILING DATE: 1999-03-25  
PRIOR APPLICATION NUMBER: 60/126,188  
PRIOR FILING DATE: 1999-03-25  
PRIOR APPLICATION NUMBER: GB 9825303.2  
PRIOR FILING DATE: 1998-11-18  
PRIOR APPLICATION NUMBER: GB 9901739.4  
PRIOR FILING DATE: 1999-01-27  
PRIOR APPLICATION NUMBER: GB 9917995.4  
PRIOR FILING DATE: 1999-07-30  
NUMBER OF SEQ ID NOS: 27  
SOFTWARE: PatentIn version 2.1  
SEQ ID NO 16  
LENGTH: 9

```
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: 574 9 Mer
US-10-774-176-16
```

```
Query Match
Best Local Similarity 66.7%; Score 34; DB 17; Length 9;
Pred. No. 1.5e+06;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 123 DDNPWT 128
DB 3 DNNPMV 8
```

RESULT 13

```
US-09-935-430-433
; Sequence 433, Application US/09935430
; Publication No. US20030017466A1
; GENERAL INFORMATION:
```

```
APPLICANT: FARIS, MARY
APPLICANT: HUBERT, RENE
APPLICANT: RAITANO, ARTHUR
APPLICANT: AFAR, DANIEL
APPLICANT: LEVIN, ELANA
APPLICANT: CHALLITA-EID, PIA
```

```
TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158PID7
TITLE OF INVENTION: USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND
FILE REFERENCE: 51158-20050.00
```

```
CURRENT APPLICATION NUMBER: US/09/935,430
```

```
PRIOR FILING DATE: 2001-08-22
```

```
PRIOR FILING DATE: 2000-08-22
```

```
PRIOR APPLICATION NUMBER: 60/282,739
```

```
NUMBER OF SEQ ID NOS: 700
```

```
SOFTWARE: PatentIn Ver. 2.1
```

```
SEQ ID NO 433
```

```
LENGTH: 10
```

```
TYPE: PRT
```

```
ORGANISM: Artificial Sequence
```

```
FEATURE:
```

```
OTHER INFORMATION: Description of Artificial Sequence: Peptide motif
US-09-935-430-433
```

```
Query Match
Best Local Similarity 1.6%; Score 34; DB 10; Length 10;
Pred. No. 1.7e+04;
Matches 5; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 96 LGLOHVVPEL 105
DB 1 VGLQOWIOKL 10
```

RESULT 14

```
US-09-809-638-585
; Sequence 585, Application US/09809638
; Publication No. US20030059895A1
; GENERAL INFORMATION:
```

```
APPLICANT: Mary Faris
```

```
APPLICANT: Pia M. Challita-Eid
```

```
APPLICANT: Steve Chappell Mitchell
```

```
APPLICANT: Daniel E.H. Afar
```

```
APPLICANT: Arthur B. Raitano
```

```
APPLICANT: Aya Jakobovits
```

```
TITLE OF INVENTION: 125P5C8: A TISSUE SPECIFIC PROTEIN
```

```
FILE REFERENCE: 129.35US01
```

```
CURRENT APPLICATION NUMBER: US/09/809,638
```

```
CURRENT FILING DATE: 2001-03-14
```

```
NUMBER OF SEQ ID NOS: 746
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 585
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-809-638-585
```

```
Query Match
Best Local Similarity 1.6%; Score 34; DB 10; Length 10;
Pred. No. 1.7e+04;
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 249 SSSYKTWGL 257
DB 1 STRYHTWGI 9
```

RESULT 15

```
US-09-809-638-680
; Sequence 680, Application US/09809638
; Publication No. US20030059895A1
; GENERAL INFORMATION:
```

```
APPLICANT: Mary Faris
```

```
APPLICANT: Pia M. Challita-Eid
```

```
APPLICANT: Steve Chappell Mitchell
```

```
APPLICANT: Daniel E.H. Afar
```

```
APPLICANT: Arthur B. Raitano
```

```
APPLICANT: Aya Jakobovits
```

```
TITLE OF INVENTION: 125P5C8: A TISSUE SPECIFIC PROTEIN
```

```
TITLE OF INVENTION: HIGHLY EXPRESSED IN VARIOUS CANCERS
```

```
FILE REFERENCE: 129.35US01
```

```
CURRENT APPLICATION NUMBER: US/09/809,638
```

```
CURRENT FILING DATE: 2001-03-14
```

```
NUMBER OF SEQ ID NOS: 746
```

```
SOFTWARE: FastSeq for Windows Version 4.0
```

```
SEQ ID NO 680
```

```
LENGTH: 10
```

```
TYPE: PRT
```

```
ORGANISM: Homo sapiens
```

```
US-09-809-638-680
```

```
Query Match
Best Local Similarity 1.6%; Score 34; DB 10; Length 10;
Pred. No. 1.7e+04;
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 249 SSSYKTWGL 257
DB 1 STRYHTWGI 9
```

```
Search completed: January 24, 2005, 14:44:51
Job time : 144 secs
```

**This Page Blank (uspio)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 24, 2005, 14:36:23 ; Search time 40 Seconds  
(without alignments)  
641.627 Million cell updates/sec

Title: US-09-744-804A-78

Perfect score: 2110  
Sequence: 1 MRPRLALGALCAPSL.....RLPVMHRLRLLELCG 387

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 110780

Minimum DB seq length: 0  
Maximum DB seq length: 10

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents AA:  
1: /cgn2\_6/prodata/1/aa/5A COMB pep:.\*  
2: /cgn2\_6/prodata/1/aa/5B COMB pep:.\*  
3: /cgn2\_6/prodata/1/aa/6A COMB pep:.\*  
4: /cgn2\_6/prodata/1/aa/6B COMB pep:.\*  
5: /cgn2\_6/prodata/1/aa/PCTUS COMB pep:.\*  
6: /cgn2\_6/prodata/1/aa/backfile1 pep:.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	42	2.0	9	1	US-08-179-481-115
2	42	2.0	10	6	5177197-8
3	39	1.8	8	3	US-08-981-392-88
4	39	1.8	8	4	US-09-908-322-88
5	37	1.8	10	1	US-08-179-481-31
6	36	1.7	7	2	US-08-162-4028-23
7	34	1.6	8	3	US-08-481-968A-29
8	34	1.6	8	3	US-08-154-7128-29
9	34	1.6	8	4	US-09-947-925A-29
10	34	1.6	9	2	US-08-764-640-69
11	34	1.6	9	3	US-08-973-225-69
12	34	1.6	9	3	US-09-244-298A-69
13	34	1.6	9	3	US-09-516-704-69
14	34	1.6	9	4	US-09-549-090-69
15	34	1.6	9	4	US-09-832-230A-69
16	34	1.6	9	4	US-09-358-856C-38
17	34	1.6	10	2	US-08-764-640-63
18	34	1.6	10	2	US-08-556-597-121
19	34	1.6	10	3	US-08-973-225-63
20	34	1.6	10	3	US-09-244-298A-63
21	34	1.6	10	3	US-09-516-704-63
22	34	1.6	10	4	US-09-549-090-63
23	34	1.6	10	4	US-09-832-230A-63
24	34	1.6	10	4	US-09-428-0828-46
25	34	1.6	10	4	US-09-563-222C-34
26	33	1.6	7	2	US-08-162-4028-22
27	33	1.6	9	2	US-08-290-268-10

28	33	1.6	10	2	US-08-764-640-122	Sequence 122, App
29	33	1.6	10	2	US-08-335-832-8	Sequence 8, App1
30	33	1.6	10	3	US-09-141-127-2	Sequence 2, App1
31	33	1.6	10	3	US-08-973-225-122	Sequence 122, App
32	33	1.6	10	3	US-09-244-298A-122	Sequence 122, App
33	33	1.6	10	3	US-09-516-704-122	Sequence 122, App
34	33	1.6	10	4	US-09-549-090-122	Sequence 122, App
35	33	1.6	10	4	US-09-832-230A-122	Sequence 122, App
36	33	1.6	10	4	US-09-535-852-1098	Sequence 1098, Ap
37	33	1.6	10	4	US-09-535-852-1370	Sequence 1370, Ap
38	32	1.5	7	4	US-09-599-846-1	Sequence 1, App1
39	32	1.5	7	6	5256643-5	Patent No. 5256643
40	32	1.5	9	1	US-07-646-531D-4	Sequence 4, App1
41	32	1.5	9	1	US-07-646-531D-19	Sequence 19, App1
42	32	1.5	9	2	US-08-488-273-4	Sequence 4, App1
43	32	1.5	9	3	US-08-142-590B-10	Sequence 10, App1
44	32	1.5	9	3	US-09-139-802-113	Sequence 113, App
45	32	1.5	9	3	US-09-197-770B-10	Sequence 10, App1

#### ALIGNMENTS

RESULT 1  
US-08-179-481-115  
; Sequence 115, Application US/08179481  
; Patent No. 5624816  
; GENERAL INFORMATION:  
; APPLICANT: CARRAWAY, KERMIT L.  
; APPLICANT: CAROTHERS CARRAWAY, CORALIE A.  
; APPLICANT: FREIGIEN, NEVIS L.  
; TITLE OF INVENTION: ONCOGENE PRODUCT LIGAND  
; NUMBER OF SEQUENCES: 125  
; CORRESPONDENCE ADDRESS: 125  
; ADDRESSES: CUSHMAN, DARBY & CUSHMAN  
; STREET: 1100 NEW YORK AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: U.S.A.  
; ZIP: 20005-3918  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US 07/922,521  
; FILING DATE: 30-JUL-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: KOKULIS, PAUL N.  
; REGISTRATION NUMBER: 16,773  
; REFERENCE/DOCKET NUMBER: 200702/UM92-08CIP  
; TELEPHONE: (202) 861-3000  
; TELEFAX: (202) 822-0944  
; TELEX: 6714627 CUSH  
; INFORMATION FOR SEQ ID NO: 115:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 9 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; US-08-179-481-115

Query Match 2.0%; Score 42; DB 1; Length 9;  
Best Local Similarity 85.7%; Pred. No. 3.8e+05;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 32 CHNGGLC 38  
Db 3 CHNGGOC 9

## RESULT 2

5177197-8  
; Patent No. 5177197  
; APPLICANT: KANZAKI, TETSUO; OLOFSSON, ANDERS; MOREN, ANITA;  
; WERNSTEDT, CHRISTER; HELLMAN, ULF; MIYAZONO, KOHEI; CLASSON-WELSH,  
; LENA; HELDIN, CARL-HENRIK  
; TITLE OF INVENTION: ISOLATED NUCLEOTIDE SEQUENCE EXPRESSING  
; HUMAN TRANSFORMING GROWTH FACTOR-BETA1-BINDING PROTEIN  
; NUMBER OF SEQUENCES: 53  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/487,343  
; FILING DATE: 27-FEB-1990  
; SEQ ID NO: 8  
; LENGTH: 10  
5177197-8

Query Match 2.0%; Score 42; DB 6; Length 10;  
Best Local Similarity 66.7%; Pred. No. 7.9e+02;  
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 53 YTCCTCLKGY 61  
Db 1 YTCCTCYEGY 9

## RESULT 3

US-08-981-392-88  
; Sequence 88, Application US/08981392  
; Patent No. 6262025  
; GENERAL INFORMATION:  
; APPLICANT: Ish-Horowitz, David  
; APPLICANT: Henrique, Domingos Manuel Pinto  
; APPLICANT: Lewis, Julian Hart  
; APPLICANT: Artavakis-Tsakonas, Spyridon  
; APPLICANT: Gray, Grace  
; TITLE OF INVENTION: NUCLEOTIDE AND PROTEIN SEQUENCES  
; TITLE OF INVENTION: OF VERTEBRATE DELTA GENES AND METHODS BASED THEREON  
; NUMBER OF SEQUENCES: 94  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Pennie & Edmonds LLP  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036/2711  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/981,392  
; FILING DATE: 22-DEC-1997  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Antler, Adriane M.  
; REGISTRATION NUMBER: 32,605  
; REFERENCE/DOCKET NUMBER: 7326-038  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 212-790-9090  
; TELEFAX: 212-869-8864  
; TELEX: 66141 PENNIE  
; INFORMATION FOR SEQ ID NO: 88:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: unknown

; MOLECULE TYPE: peptide  
US-08-981-392-88

Query Match 1.8%; Score 39; DB 3; Length 8;  
Best Local Similarity 85.7%; Pred. No. 3.8e+05;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 30 NPCHNGG 36  
Db 1 NPCKNGG 7

## RESULT 4

US-09-908-322-88  
; Sequence 88, Application US/09908322  
; Patent No. 6783956  
; GENERAL INFORMATION:  
; APPLICANT: Ish-Horowitz, David  
; Henrique, Domingos Manuel Pinto  
; Lewis, Julian Hart  
; Artavakis-Tsakonas, Spyridon  
; Gray, Grace

TITLE OF INVENTION: NUCLEOTIDE AND PROTEIN SEQUENCES OF  
VERTEBRATE DELTA GENE AND METHODS BASED THEREON

NUMBER OF SEQUENCES: 94  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Pennie & Edmonds LLP  
STREET: 1155 Avenue of the Americas  
CITY: New York  
STATE: NY

COUNTRY: USA

ZIP: 10036/2711

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSeq Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/908,322

FILING DATE: 17-Jul-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/981,392

FILING DATE: 22-DEC-1997

ATTORNEY/AGENT INFORMATION:

NAME: Mirock, S Leslie

REGISTRATION NUMBER: 18,872

REFERENCE/DOCKET NUMBER: 7326-123

TELECOMMUNICATION INFORMATION:

TELEPHONE: 212-790-9090

TELEFAX: 212-869-8864

TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 88:

SEQUENCE CHARACTERISTICS:

LENGTH: 8 amino acids

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: unknown

MOLECULE TYPE: peptide

SEQUENCE DESCRIPTION: SEQ ID NO: 88:

Query Match 1.8%; Score 39; DB 4; Length 8;  
Best Local Similarity 85.7%; Pred. No. 3.8e+05;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 30 NPCHNGG 36  
Db 1 NPCKNGG 7

## RESULT 5

US-08-179-481-31

Sequence 31, Application US/08179481  
Patent No. 5624816  
GENERAL INFORMATION:  
APPLICANT: CARRAWAY, KERMIT L.  
APPLICANT: CAROTHERS, CARRAWAY, CORALIE A.  
APPLICANT: FREGIEN, NEVIS L.  
TITLE OF INVENTION: ONCOGENE PRODUCT LIGAND  
NUMBER OF SEQUENCES: 125  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: CUSHMAN, DARBY & CUSHMAN  
STREET: 1100 NEW YORK AVENUE, N.W.  
CITY: WASHINGTON  
STATE: D.C.  
COUNTRY: U.S.A.  
ZIP: 20005-3918  
TELEPHONE: 202-638-1918  
TELEFAX: 202-638-1919  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/179,481  
FILING DATE: 28-DEC-1993  
CLASSIFICATION: 435  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US 07/922,521  
FILING DATE: 30-JUL-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: KORULIS, PAUL N.  
REGISTRATION NUMBER: 16,773  
REFERENCE/DOCKET NUMBER: 200702/UM92-08CIP  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 861-3000  
TELEFAX: (202) 822-0944  
TELEX: 6714627 CUSH  
INFORMATION FOR SEQ ID NO: 31:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 10 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-179-481-31

Query Match 1.8%; Score 37; DB 1; Length 10;  
Best Local Similarity 85.7%; Pred. No. 2.3e+03;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 NPCHNG 36  
DB 3 NPCLNG 9

RESULT 6  
US-08-162-402B-23  
Sequence 23, Application US/08162402B  
Patent No. 5972337  
GENERAL INFORMATION:  
APPLICANT: CERTANI, ROBERTO L.  
APPLICANT: PETERSON, JERRY A.  
APPLICANT: LAROCCA, DAVID J.  
TITLE OF INVENTION: 46 KDALTON HUMAN MILK FAT  
TITLE OF INVENTION: GLOBULE (HMF) ANTIGEN, FRAGMENTS & FUSION PROTEIN  
NUMBER OF SEQUENCES: 29  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Pretty, Schroeder & Poplawski  
STREET: 444 South Flower St., 19th Floor  
CITY: Los Angeles  
STATE: CA  
COUNTRY: USA  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/162,402B  
FILING DATE: 03-DEC-1993  
CLASSIFICATION: 435  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Amzel, Viviana  
REGISTRATION NUMBER: 30,930  
REFERENCE/DOCKET NUMBER: P66 38215  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 213-622-7700  
TELEFAX: 213-489-4210  
TELEX:  
INFORMATION FOR SEQ ID NO: 23:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 7 amino acids  
TYPE: amino acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: peptide  
US-08-162-402B-23

Query Match 1.7%; Score 36; DB 2; Length 7;  
Best Local Similarity 85.7%; Pred. No. 3.8e+05;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 101 WVEPLAR 107  
DB 1 WVEPLAR 7

RESULT 7  
US-08-481-968A-29  
Sequence 29, Application US/08481968A  
Patent No. 6300490  
GENERAL INFORMATION:  
APPLICANT: Huber, Brian  
APPLICANT: Richards, Cynthia  
TITLE OF INVENTION: Molecular Constructs Comprising a Carcinoembryonic Antigen (CEA)  
TITLE OF INVENTION: Transcriptional Regulatory Region  
FILE REFERENCE: PB1087US4  
CURRENT APPLICATION NUMBER: US/08/481,968A  
CURRENT FILING DATE: 1998-06-07  
NUMBER OF SEQ ID NOS: 36  
SOFTWARE: Patent in version 3.0  
SEQ ID NO 29  
LENGTH: 8  
TYPE: PRT  
ORGANISM: Consensus sequence  
FEATURE:  
NAME/KEY: misc feature  
OTHER INFORMATION: Consensus sequence F6 from transcriptional dictionary of Locker a  
US-08-481-968A-29

Query Match 1.6%; Score 34; DB 3; Length 8;  
Best Local Similarity 71.4%; Pred. No. 3.8e+05;  
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 211 SCHTACT 217  
DB 1 TCMYACT 7

RESULT 8  
US-08-154-712B-29  
Sequence 29, Application US/08154712B  
Patent No. 6337209

```

; GENERAL INFORMATION:
; APPLICANT: Huber, Brian
; APPLICANT: Richards, Cynthia
; TITLE OF INVENTION: Molecular Constructs Containing a Carcinoembryonic Antigen Regu
; TITLE OF INVENTION: Sequence
; FILE REFERENCE: PB1087US3
; CURRENT APPLICATION NUMBER: US/08/154,712B
; CURRENT FILING DATE: 1993-11-19
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 29
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Consensus sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Consensus sequence F6 from transcriptional dictionary of Locker a
; OTHER INFORMATION: nd Buzard (1990).
; US-08-154-712B-29

Query Match 1.6%; Score 34; DB 3; Length 8;
Best Local Similarity 71.4%; Pred. No. 3.8e+05;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 211 SCHATCT 217
Db 1 TCNTACT 7

RESULT 9
US-09-947-925A-29
; Sequence 29, Application US/09947925A
; Patent No. 6699690
; GENERAL INFORMATION:
; APPLICANT: Huber, Brian
; APPLICANT: Richards, Cynthia
; TITLE OF INVENTION: Molecular Constructs Containing a Carcinoembryonic
; TITLE OF INVENTION: Antigen Regulatory
; TITLE OF INVENTION: Sequence
; FILE REFERENCE: PB1087US3
; CURRENT APPLICATION NUMBER: US/09/947,925A
; CURRENT FILING DATE: 2001-09-06
; PRIOR APPLICATION NUMBER: US/08/154,712
; PRIOR FILING DATE: 1993-11-19
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 29
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Consensus sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Consensus sequence F6 from transcriptional dictionary
; OTHER INFORMATION: of Locker a
; OTHER INFORMATION: nd Buzard (1990).
; US-09-947-925A-29

Query Match 1.6%; Score 34; DB 4; Length 8;
Best Local Similarity 71.4%; Pred. No. 3.8e+05;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 211 SCHATCT 217
Db 1 TCNTACT 7

RESULT 10
US-08-764-640-69
; Sequence 69, Application US/08764640
; Patent No. 5869451
; Patent No. 5869451 5837683
; GENERAL INFORMATION:
; APPLICANT: Dower, William J.
```

```

; APPLICANT: Barrett, Ronald W.
; APPLICANT: Cwiria, Steven E.
; APPLICANT: Gates, Christian
; APPLICANT: Schatz, Peter J.
; APPLICANT: Balasubramanian, Palaniappan
; APPLICANT: Wagstrom, Christopher R.
; APPLICANT: Hendren, Richard R.
; APPLICANT: Depierre, Randolph B.
; APPLICANT: Podcuturi, Surekha
; APPLICANT: Yin, Qun
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
; TITLE OF INVENTION: RECEPTOR
; NUMBER OF SEQUENCES: 244
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Glaxo Wellcome
; STREET: Five Moore Drive, P.O. Box 13398
; CITY: Research Triangle Park
; STATE: NC
; COUNTRY: USA
; ZIP: 27709
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/764,640
; FILING DATE: 11-DEC-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Hrudiac, Robert T.
; REGISTRATION NUMBER: 36,392
; REFERENCE/DOCKET NUMBER: PK3281
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-248-1000
; INFORMATION FOR SEQ ID NO: 69:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-764-640-69

Query Match 1.6%; Score 34; DB 2; Length 9;
Best Local Similarity 46.7%; Pred. No. 3.8e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

QY 216 CTIRFELGCEIENGCC 230
Db 1 CTLEF-----MNGC 9

RESULT 11
US-08-973-225-69
; Sequence 69, Application US/08973225A
; Patent No. 6083913
; GENERAL INFORMATION:
; APPLICANT: Dower, William J.
; APPLICANT: Barrett, Ronald W.
; APPLICANT: Cwiria, Steven E.
; APPLICANT: Duffin, David J.
; APPLICANT: Gates, Christian
; APPLICANT: Haselden, Sherril S.
; APPLICANT: Matcheakie, Larry C.
; APPLICANT: Schatz, Peter J.
; APPLICANT: Wagstrom, Christopher R.
; APPLICANT: Wrighton, Nicholas C.
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
; TITLE OF INVENTION: THROMBOPOIETIN RECEPTOR
; NUMBER OF SEQUENCES: 232
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Glaxo Wellcome
```

STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park  
STATE: NC  
COUNTRY: USA  
ZIP: 27709  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/973,225A  
FILING DATE: 04-Dec-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PK3065USW  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000  
INFORMATION FOR SEQ ID NO: 69:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 9 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 69:  
US-08-973-225-69

Query Match 1.6%; Score 34; DB 3; Length 9;  
Best Local Similarity 46.7%; Pred. No. 3.8e+05;  
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

QY 216 CTLPFELGCELNGC 230  
DB 1 CTLEF-----MNGC 9

RESULT 12  
US-09-244-298A-69  
Sequence 69, Application US/09244298A  
Patent No. 6121238  
GENERAL INFORMATION:  
APPLICANT: Dower, William J.  
APPLICANT: Barrett, Ronald W.  
APPLICANT: Cwiria, Steven E.  
APPLICANT: Gates, Christian  
APPLICANT: Schatz, Peter J.  
APPLICANT: Balasubramanian, Palaniappan  
APPLICANT: Magstrom, Christopher R.  
APPLICANT: Hendren, Richard W.  
APPLICANT: Deprince, Randolph B.  
APPLICANT: Podduturi, Surekha  
TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
TITLE OF INVENTION: RECEPTOR  
NUMBER OF SEQUENCES: 244  
CORRESPONDENCE ADDRESS:  
ADDRESSER: Glaxo Wellcome  
STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park  
STATE: NC  
COUNTRY: USA  
ZIP: 27709  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/244,298A  
FILING DATE: 11-DEC-1996  
CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:  
NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PK3281  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000  
INFORMATION FOR SEQ ID NO: 69:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 9 amino acids  
TYPE: amino acid  
STRANDEDNESS:  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-09-244-298A-69

Query Match 1.6%; Score 34; DB 3; Length 9;  
Best Local Similarity 46.7%; Pred. No. 3.8e+05;  
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

QY 216 CTLPFELGCELNGC 230  
DB 1 CTLEF-----MNGC 9

RESULT 13  
US-09-516-704-69  
Sequence 69, Application US/09516704  
Patent No. 6251864  
GENERAL INFORMATION:  
APPLICANT: Dower, William J.  
APPLICANT: Barrett, Ronald W.  
APPLICANT: Cwiria, Steven E.  
APPLICANT: Gates, Christian  
APPLICANT: Schatz, Peter J.  
APPLICANT: Balasubramanian, Palaniappan  
APPLICANT: Magstrom, Christopher R.  
APPLICANT: Hendren, Richard W.  
APPLICANT: Deprince, Randolph B.  
APPLICANT: Podduturi, Surekha  
TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
TITLE OF INVENTION: RECEPTOR  
NUMBER OF SEQUENCES: 244  
CORRESPONDENCE ADDRESS:  
ADDRESSER: Glaxo Wellcome  
STREET: Five Moore Drive, P.O. Box 13398  
CITY: Research Triangle Park  
STATE: NC  
COUNTRY: USA  
ZIP: 27709  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/516,704  
FILING DATE: 01-Mar-2000  
CLASSIFICATION: <Unknown>  
ATTORNEY/AGENT INFORMATION:  
NAME: Hrubiec, Robert T.  
REGISTRATION NUMBER: 36,392  
REFERENCE/DOCKET NUMBER: PK3281  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-248-1000  
INFORMATION FOR SEQ ID NO: 69:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 9 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 69:  
US-09-516-704-69

Query Match 1.6%; Score 34; DB 3; Length 9;  
Best Local Similarity 46.7%; Pred. No. 3.8e+05;  
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

OY 216 CTRFELLGCEINGC 230  
1 CTRF-----MNGC 9

## RESULT 14

US-09-549-090-69  
; Sequence 69, Application US/09549090  
; Patent No. 6465430  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J.  
; Barrett, Ronald W.  
; Cwifla, Steven F.  
; Duffin, David J.  
; Gates, Christian  
; Haseiden, Sherril S.  
; Matheakis, Larry C.  
; Schatz, Peter J.  
; Wagstrom, Christopher R.  
; Wrighton, Nicholas C.  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; WRIGHTON, NICHOLAS C.  
; NUMBER OF SEQUENCES: 232  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/549, 090  
; FILING DATE: 13-Apr-2000  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/973, 225  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hrubiec, Robert T.  
; REGISTRATION NUMBER: 36,392  
; REFERENCE/DOCKET NUMBER: PK3065USW  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 919-248-1000  
; INFORMATION FOR SEQ ID NO: 69:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 9 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: <Unknown>  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 69:  
US-09-549-090-69

Query Match 1.6%; Score 34; DB 4; Length 9;  
Best Local Similarity 46.7%; Pred. No. 3.8e+05;  
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

OY 216 CTRFELLGCEINGC 230  
1 CTRF-----MNGC 9

RESULT 15  
US-09-832-230A-69

; Sequence 69, Application US/09832230A  
; Patent No. 6506362  
; GENERAL INFORMATION:  
; APPLICANT: Dower, William J. et al  
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A  
; RECEPTOR  
; NUMBER OF SEQUENCES: 244  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Glaxo Wellcome  
; STREET: Five Moore Drive, P.O. Box 13398  
; CITY: Research Triangle Park  
; STATE: NC  
; COUNTRY: USA  
; ZIP: 27709  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/832,230A  
; FILING DATE: 10-Apr-2001  
; CLASSIFICATION: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hrubiec, Robert T.  
; REGISTRATION NUMBER: 36,392  
; REFERENCE/DOCKET NUMBER: PK3281  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 919-248-1000  
; INFORMATION FOR SEQ ID NO: 69:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 9 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: <Unknown>  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 69:  
US-09-832-230A-69

Query Match 1.6%; Score 34; DB 4; Length 9;  
Best Local Similarity 46.7%; Pred. No. 3.8e+05;  
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

OY 216 CTRFELLGCEINGC 230  
1 CTRF-----MNGC 9

Search completed: January 24, 2005, 14:45:43  
Job time : 48 secs